阅读说明：本技术 包含亲水性活性剂颗粒的半固体多相口腔组合物 (Semi-solid multi-phase oral compositions comprising particles of hydrophilic active agent ) 是由 P·A·萨格尔 J·拉加伊亚 M·D·柯蒂斯 于 2020-04-08 设计创作，主要内容包括：本发明公开了一种用于口腔中的半固体分散体形式的半固体多相口腔组合物。所述半固体口腔分散体包含在疏水相中的亲水性活性剂颗粒。所述亲水性活性剂颗粒可包含漂白剂、抗微生物剂、抗牙结石剂和/或它们的组合。(A semi-solid multi-phase oral composition in the form of a semi-solid dispersion for use in the oral cavity is disclosed. The semi-solid oral dispersion comprises hydrophilic active agent particles in a hydrophobic phase. The hydrophilic active agent particles can comprise a bleaching agent, an antimicrobial agent, an anticalculus agent, and/or combinations thereof.)

1. A semi-solid multi-phase oral composition comprising:

a) from about 0.001% to about 50%, by weight of the multi-phase oral composition, of particles of a hydrophilic active agent; and

b) at least about 50%, by weight of the multi-phase oral composition, of a hydrophobic phase;

wherein the hydrophobic phase and/or the semi-solid multi-phase oral composition has a cone penetration consistency value of from about 25 to about 300; and wherein the semi-solid multi-phase oral composition is a semi-solid dispersion.

2. A semi-solid multiphase oral composition according to claim 1, wherein at least about 20 parts by weight of the hydrophilic active agent particles, preferably at least about 50 parts by weight of the hydrophilic active agent particles, more preferably at least about 60 parts by weight of the hydrophilic active agent particles, more preferably at least about 70 parts by weight of the hydrophilic active agent particles, and more preferably at least about 80 parts by weight of the hydrophilic active agent particles are soluble in about 100 parts by weight of water and/or the hydrophilic active agent particles swell upon contact with water by at least about 20%, preferably at least about 50%, more preferably at least about 60%, more preferably at least about 70%, and more preferably at least about 80%.

3. The semi-solid multi-phase oral composition of claim 1 or 2, wherein hydrophilic active agent particles are insoluble in the hydrophobic phase, and the hydrophobic phase is insoluble in water.

4. The semi-solid multi-phase oral composition according to any one of the preceding claims, wherein the hydrophobic phase or the cone penetration consistency value of the multi-phase oral composition is from about 50 to about 250, preferably from about 100 to about 200, and/or wherein the drop melting point of the hydrophobic phase is from about 40 ℃ to about 120 ℃, preferably from about 50 ℃ to about 100 ℃, more preferably from about 50 ℃ to about 90 ℃, more preferably from about 60 ℃ to about 80 ℃.

5. The semi-solid multi-phase oral composition of any one of the preceding claims, wherein the hydrophilic active agent particles in the semi-solid multi-phase oral composition comprise at least one of a healing agent, an anticalculus agent, an anticaries agent, an antimicrobial agent, a dentinal desensitizing agent, an anesthetic agent, an antifungal agent, a cooling agent, an anti-inflammatory agent, a selective H-2 antagonist, a nutrient, erythritol, a probiotic, a hydrophilic bleaching agent, a tooth whitening agent, or a combination thereof, preferably wherein the hydrophilic active agent particles comprise at least one of an anticaries agent, an antimicrobial agent, or a combination thereof.

6. The semi-solid multiphase oral composition of claim 5, wherein the anticaries agent comprises at least one of xylitol or a fluoride ion source that provides free fluoride ions, wherein the fluoride ion source is preferably selected from sodium fluoride, stannous fluoride, indium fluoride, organic fluorides such as amine fluoride, sodium monofluorophosphate, and combinations thereof, more preferably wherein the fluoride ion source is sodium fluoride, stannous fluoride, or combinations thereof.

7. The semi-solid multi-phase oral composition of claim 5 or 6, wherein the antimicrobial agent comprises triclosan; 5-chloro-2- (2, 4-dichlorophenoxy) -phenol; chlorhexidine; alexidine; a hexetidine; sanguinarine; benzalkonium chloride; salicylanilide; domiphen bromide; cetylpyridinium chloride (CPC); tetradecylpyridine chloride (TPC); n-tetradecyl-4-ethylpyridine chloride (TDEPC); decadicaprylidine; at least one of delmopinol, octapinol, or piperidino derivatives, essential oils, antimicrobial metals, or combinations thereof, wherein the antimicrobial metal preferably comprises zinc, tin, copper, or combinations thereof, more preferably wherein the antimicrobial metal is tin, even more preferably selected from at least one of stannous fluoride, stannous chloride, stannous gluconate, and combinations thereof.

8. The semi-solid multiphase oral composition of any one of claims 5 to 7, wherein the healing agent comprises at least one of hyaluronic acid or salt, glucosamine or salt, allantoin, curcumin, D-panthenol, nicotinamide, ellagic acid, flavonoids, or combinations thereof, preferably wherein the flavonoids comprise at least one of fisetin, quercetin, luteolin, apigenin, vitamin E, ubiquinone, or combinations thereof.

9. The semi-solid multi-phase oral composition of any one of claims 5 to 8, wherein the probiotic comprises Lactobacillus reuteri ATCC 55730; lactobacillus salivarius strain TI12711(LS 1); lactobacillus paracasei ADP-1; streptococcus salivarius K12; bifidobacterium DN-173010; filtrate of Lactobacillus paracasei strain (pro-t-action)^™) (ii) a Streptococcus oralis KJ3, streptococcus rat JH145, streptococcus uberis KJ 2; lactobacillus reuteri mutants; lactobacillus salivarius LS 1; lactobacillus paracasei; lactobacillus paracasei ADP 1; streptococcus salivarius M18, K12 or BLISs K12 and BLISs M18; bacillus amyloliquefaciens; bacillus clausii; bacillus coagulans; b, bacillus subtilis; b, bacillus subtilis: e-300; bifidobacterium animalis; bifidobacterium B6; bifidobacterium bifidum; bifidobacterium breve (Bb-03); bifidobacterium DN-173010; bifidobacterium GBI 306068; bifidobacterium infantis; bifidobacterium lactis; bifidobacterium lactis Bb-12; bifidobacterium longum; bifidobacterium thermophilum; enterococcus faecalis; enterococcus faecium; enterococcus faecium NCIMB 10415; enterococcus LAB SF 68; lactobacillus reuteri ATCC55730 and ATCC PTA 5289; lactobacillus reuteri ATCC55730 and ATCC PTA 5289(10: 1); lactobacillus acidophilus; lactobacillus acidophilus ATCC 4356 and bifidobacterium bifidum ATCC 29521; lactobacillus acidophilus; bifidobacterium longum; bifidobacterium bifidum; bifidobacterium lactis; lactobacillus brevis; lactobacillus casei (subspecies Casi); lactobacillus casei field strain; fusing lactobacillus; lactobacillus crispatus YIT 12319; lactobacillus curvatus; lactobacillus delbrueckii subsp bulgaricus PXN 39; lactobacillus fermentum; lactobacillus fermentum YIT 12320; lactobacillus gasseri; lactobacillus gasseri YIT 12321; lactobacillus helveticus; lactobacillus johnsonii; lactobacillus sauerkraut; lactobacillus lactis L1A; lactobacillus paracasei (Lpc 37); lactobacillus paracasei GMNL-33; lactobacillus pentosus; lactobacillus plantarum; lactobacillus plantarum; lactobacillus Protectus; lactobacillus reuteri; lactobacillus reuteri ATCC 55730; lactobacillus reuteri SD2112(ATCC 55730); lactobacillus rhamnosus (GG); rhamnose milk barBacterium GG; lactobacillus rhamnosus GG; lactobacillus rhamnosus LC 705; propionibacterium freudenreichii subspecies; JS of xie; lactobacillus rhamnosus L8020; lactobacillus rhamnosus LB 21; lactobacillus salivarius; lactobacillus salivarius WB 21; a lactic acid bacterium of the bacillus; lactococcus lactis diacetyl subspecies; lactococcus lactis subsp lactis; pediococcus acidilactici; pediococcus pentosaceus; (ii) saccharomyces boulardii; saccharomyces cerevisiae; streptococcus uberis KJ2 sm; streptococcus oralis KJ3 sm; streptococcus rat JH 145; streptococcus mitis YIT 12322; streptococcus oralis KJ 3; streptococcus rat JH 145; streptococcus salivarius (BLISs K12 or BLISs M18); streptococcus salivarius K12; streptococcus thermophilus; streptococcus uberis KJ 2; thermophilic thermus; weissella civora CMS 2; weissella civora CMS 3; or Weissella ciutu or a combination thereof.

10. The semi-solid multi-phase oral composition of any one of claims 5 to 9, wherein the anti-calculus agent comprises a polyphosphate and salts thereof; polyaminopropane sulfonic Acid (AMPS) and salts thereof; polyolefin sulfonates and salts thereof; polyvinyl phosphates and salts thereof; polyolefin phosphates and salts thereof; diphosphonates and salts thereof; phosphonoalkane carboxylic acids and salts thereof; polyphosphonates and salts thereof; polyvinyl phosphonates and salts thereof; polyolefin phosphonates and salts thereof; or a polypeptide and combinations thereof, preferably including at least one of pyrophosphate, polyphosphate, polyphosphonate, and combinations thereof.

11. The semi-solid multiphase oral composition of any one of claims 5 to 10, wherein the cooling agent comprises at least one of a desensitizing agent or numbing agent, preferably formamide, p-menthane carboxamide, menthol, ketals, diols and mixtures thereof, more preferably N-ethyl-p-menthane-3-carboxamide, N,2, 3-trimethyl-2-isopropylbutanamide, menthol, 3-1-menthoxypropane-1, 2-diol, menthone glycerol acetal, menthyl lactate and combinations thereof.

12. A semi-solid multi-phase oral composition according to any one of claims 5 to 11, wherein the anti-inflammatory agent comprises at least one of a non-steroidal anti-inflammatory agent such as aspirin, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, ketoprofen, piroxicam and meclofenamic acid, a COX-2 inhibitor, preferably valdecoxib, celecoxib and rofecoxib, or a combination thereof.

13. The semi-solid multi-phase oral composition of any one of claims 5 to 12, wherein the hydrophilic active agent particles in the semi-solid multi-phase oral composition comprise hydrophilic bleach particles, preferably wherein the hydrophilic bleach particles are hydrogen peroxide adducts, more preferably wherein the hydrogen peroxide adducts comprise urea peroxide, polyvinylpyrrolidone complexed with hydrogen peroxide, or a combination thereof.

14. The semi-solid multi-phase oral composition of any one of the preceding claims, wherein the hydrophobic phase comprises at least one of: mineral oil thickened with wax, mineral oil thickened with polyethylene, petrolatum, or a combination thereof, preferably wherein the hydrophobic phase comprises petrolatum, more preferably wherein the hydrophobic phase is petrolatum.

15. The semi-solid multi-phase oral composition of any preceding claim for delivering a health benefit to the oral cavity, preferably for reducing and/or removing caries, plaque, tartar and stains, promoting gum health, preventing and treating dental cavities, improving breath, promoting whitening and/or combinations thereof.

16. A kit comprising the semi-solid multi-phase oral composition according to any one of the preceding claims and a delivery vehicle (10), preferably wherein the delivery vehicle (10) is a strip, a film of material, a tray, a sponge material, an applicator, or a combination thereof.

17. The kit of claim 16, further comprising a source of electromagnetic radiation capable of directing electromagnetic radiation having one or more wavelengths in the range of about 200nm to about 1700nm to at least one tooth, preferably wherein the source of electromagnetic radiation emits electromagnetic radiation in the range of about 400nm to about 500nm, more preferably in the range of about 175mW/cm2 to about 225mW/cm2 impinging on the outer surface of the delivery vehicle of electromagnetic radiation in the range of about 400nm to about 500nm, as measured using the procedure described herein.

Technical Field

The present invention relates to semi-solid multi-phase oral compositions in the form of dispersions comprising an active agent, in particular particles of a hydrophilic active agent suitable for use in the oral cavity.

Background

Currently on the market are dental articles with which various cosmetic and/or therapeutic actives are delivered to the teeth and oral cavity. Examples of such products include: tooth brushing aids such as dentifrice products for delivering oral care actives such as polyphosphates or fluorides; mouthwashes comprising breath fresheners or antibacterial actives; and whitening strips for delivering a bleach active to teeth. In particular, the use of dental strips to deliver cosmetic or treatment benefits to teeth and oral mucosal surfaces has been recognized as a convenient and economical method. For example, tooth whitening strips achieve continuous contact between the teeth and the whitening composition, wherein the whitening composition is first applied to the strip and then to the teeth.

Despite the above-mentioned known methods for treating oral diseases, in particular for whitening teeth or applying fluoride, there is still a need to provide products with improved bleaching efficacy, increased whitening speed, higher fluoride retention, reduced tooth sensitivity and/or reduced soft tissue irritation of the oral cavity. The prior art generally attempts to solve these problems by increasing the amount of active agent in the composition. However, this method has some problems. First, the participants may perceive an increase in irritation and/or sensitivity associated with the use of increased amounts of active agent. Furthermore, some regulatory agencies and laws around the world do not allow certain actives, such as bleach, to be used in products in amounts exceeding a certain concentration. Thus, despite the above-mentioned known methods for treating oral diseases, in particular for whitening teeth, there is still a need to provide products with improved bleaching efficacy, increased whitening speed, reduced tooth sensitivity and/or reduced oral soft tissue irritation. The present invention overcomes some of the limitations of the prior art and relates to a semi-solid multi-phase oral composition in the form of a dispersion comprising particles of a hydrophilic active agent and a hydrophobic phase, wherein the hydrophobic phase is in a predominant proportion relative to the particles of the hydrophilic active agent.

Disclosure of Invention

The present invention provides a multi-phase oral composition in the form of a semi-solid dispersion comprising from about 0.001% to about 50%, by weight of the multi-phase oral composition, of particles of a hydrophilic active agent and at least about 50%, by weight of the multi-phase oral composition, of a hydrophobic phase; wherein at least about 20 parts by weight of the hydrophilic active agent particles are soluble in about 100 parts by weight water and/or the hydrophilic active agent particles swell at least about 20% upon contact with water. Accordingly, the present invention provides a semi-solid oral dispersion comprising solid hydrophilic active agent particles; and at least about 50% hydrophobic phase by weight of the dispersion.

The present invention can be used to deliver health, therapeutic or cosmetic benefits to the oral cavity by applying the composition directly to the teeth. Further, the composition may be applied via a delivery vehicle, such as a strip or film of material, a dental tray, a sponge material, or mixtures thereof. The delivery vehicle may be attached to the teeth via the compositions herein or the adhesive function may be provided independently of the compositions herein (e.g., may be provided by a separate adhesive composition used with the inventive compositions and delivery vehicle).

The delivery vehicle may be attached to the teeth via an attachment device that is part of the delivery vehicle, e.g., the delivery vehicle may optionally be of sufficient size such that upon application, the delivery vehicle and oral soft tissue overlap, rendering more tooth surface available for the effect achieved by the active agent. The delivery vehicle may also be attached to the oral cavity by physical interference or mechanical interlocking between the delivery vehicle and oral surfaces, including teeth.

Drawings

Fig. 1 is a perspective view of a delivery system 10 comprising a strip of material 12 having rounded corners when a composition of the present invention is applied in a second layer 14.

FIG. 2 is a cross-sectional view taken along section line 2-2 of FIG. 1, showing an example of a strap.

Fig. 3 is a cross-sectional plan view illustrating the delivery system 10 attached to the tooth 22 with the composition of the second layer 14 positioned between the tooth 22 and the strip of material 12.

Fig. 4 is a cross-sectional elevation view of a tooth, taken along section line 4-4 of fig. 3, illustrating delivery system 10 adhered to tooth 22.

Figure 5 illustrates a dental tray 30 suitable for use with the compositions of the present invention.

FIG. 6 illustrates a method for delivering electromagnetic radiation having a peak intensity wavelength of about 455nm to a transparent mouthpiece, according to certain embodiments of the present invention; to facilitate reproducible positioning of the electromagnetic radiation towards the tooth surface.

Detailed Description

Without being bound by theory, it has surprisingly been found that hydrophilic active agent particles are effective at very low concentrations if present in a semi-solid multi-phase oral composition as disclosed herein. The present invention comprises from about 0.001% to about 50%, by weight of the multi-phase oral composition, of particles of a hydrophilic active agent, and a hydrophobic phase; wherein the hydrophilic active agent particles are soluble in water, swell upon contact with water, and/or release the active agent upon contact with water.

The multiphase composition can be a semi-solid dispersion of hydrophilic active agent particles comprising a bleaching agent, an antimicrobial agent, and/or an anticaries agent in a liquid or semi-solid hydrophobic phase. Without being bound by theory, it is believed that when the semi-solid dispersion contacts the surface of the tooth, the particles of hydrophilic active agent stabilized within the dispersion deliver the hydrophilic active agent to the hydrophilic biofilm on the surface of the tooth. This can lead to increased active efficacy, such as whitening teeth with lower total levels of active agent.

As used herein, by "oral care composition" is meant a product that is not intentionally swallowed for purposes of systemic administration of a particular therapeutic agent during ordinary use, but is rather retained in the oral cavity for a time sufficient to contact the tooth surfaces or oral tissues. Examples of oral care compositions include dentifrices, gums, subgingival gels, mouthwashes, mousses, foams, mouth sprays, lozenges, chewable tablets, chewing gums, tooth whitening strips, dental floss and floss coatings, breath freshening dissolvable strips, denture care products, or denture adhesive products. The oral care composition may also be incorporated onto a strip or film for direct application or attachment to an oral surface.

As used herein, the term "dentifrice" includes a tooth or subgingival paste, gel, or liquid formulation, unless otherwise specified. The dentifrice composition may be a single phase composition, or may be a combination of two or more separate dentifrice compositions. The dentifrice composition may be in any desired form, such as deep striped, light striped, multi-layered, gelled around a paste, or any combination thereof. In a dentifrice comprising two or more individual dentifrice compositions, each dentifrice composition may be contained in a physically separate dispenser compartment and dispensed side-by-side.

As used herein, the term "immiscible" or "insoluble" means that less than 1 part by weight of a substance is dissolved in 100 parts by weight of a second substance.

As used herein, the term "solubility" is the maximum weight part amount of a substance that is soluble in 100 weight parts of a second substance.

As used herein, the term "phase" refers to one or more physically distinct regions, which may be continuous or discontinuous, having one or more characteristics that are different from another phase. Non-limiting examples of characteristics that may differ between phases include composition, viscosity, solubility, hydrophobicity, hydrophilicity, and miscibility. Examples of phases include solids, liquids, and gases.

As used herein, the term "multi-phase oral composition" comprises a mixture of two or more phases that are immiscible with each other, such as a dispersion of hydrophilic active agent particles in a hydrophobic phase. The phases may be continuous, discontinuous, or a combination thereof. Examples of multi-phase oral compositions include dispersions, such as suspensions and sols. The multiphase oral composition or phases of the multiphase oral composition can be solid, liquid, semi-solid, or a combination thereof. In particular, the multi-phase oral composition as disclosed herein is a semi-solid. Examples of multi-phase oral compositions also include compositions wherein the phase is multiple continuous, including bicontinuous, layered, striped, marbled, ribbon-like, swirled, and combinations thereof.

As used herein, the term "dispersion" is an example of a semi-solid multi-phase oral composition, wherein: 1) at least one of the phases is discontinuous, and 2) at least one of the phases is continuous. Examples of dispersions include particles of hydrophilic active agent dispersed in a hydrophobic phase. In this embodiment, the hydrophilic active agent particles and the hydrophobic phase will be immiscible with each other, the hydrophilic active agent particles will be a discontinuous phase, and the hydrophobic phase will be a continuous phase.

As used herein, the term "heterogeneous mixture" is a heterogeneous combination of two or more substances. An example of a heterogeneous mixture includes hydrophilic active agent particles dispersed in a hydrophobic phase. Heterogeneous mixtures do not include homogeneous mixtures (such as solutions in which the solute is uniformly dissolved in a solvent).

As used herein, the term "heterogeneous dispersion" is a heterogeneous combination of two or more substances. Examples of heterogeneous dispersions include particles of hydrophilic active agent dispersed in a hydrophobic phase. Heterogeneous dispersions do not include homogeneous dispersions (such as solutions in which the solute is uniformly dissolved in a solvent).

As used herein, the term "particle" is a discrete, solid, or semi-solid material. The solid particles have a size greater than a single atom or molecule, and their largest dimension is typically from submicron to about one millimeter. Further, the particles may agglomerate into agglomerates of discrete particles. Preferred particles may have a size or number average equivalent diameter or volume average equivalent diameter of about 50nm to about 1 mm.

As used herein, the term "solid" is a material having the following properties at room temperature: 1) has defined dimensions, even when it is not constrained in a container; or 2) retain its original shape when it is picked up from a surface and subsequently placed back onto the surface. Examples of solids include carbamide peroxide, and complexes of hydrogen peroxide with polyvinyl pyrrolidone polymers.

As used herein, the term "preformed sheet" refers to a composition that has been formed into a sheet suitable for fitting to the oral cavity. The preformed sheet is solid once formed.

As used herein, the term "stick product" refers to a composition of a substantially solid strip of material held within a dispensing container that retains its structural integrity and shape when applied to a surface to be treated. When a portion of the stick is dragged across the surface, the film of the stick composition is transferred to the surface. Examples include lip balms and lipsticks.

As used herein, the term "liquid" is a material having the following properties at room temperature: 1) flow under gravity, or 2) take on the shape of the container in which it is placed. Examples of liquids include mineral oil, water, and silicone oil.

As used herein, the term "semi-solid" is a material having the following properties at room temperature: 1) have some solid-like properties and some liquid-like properties, or 2) their ability to meet the above definition of solid or liquid may depend on the amount of material being evaluated, e.g., a small amount of petrolatum placed in a large container may not flow under the force of gravity, and it may not take the shape of the container (and thus does not meet the definition of liquid); a large amount of petrolatum placed in a large container may flow under the force of gravity or it may take the shape of the container (thus satisfying the definition of liquid). Examples of semi-solids include petrolatum, toothpaste, silicone gel, mayonnaise, lotions, and butter. Examples of semi-solids may also include materials having cone penetration consistency values of about 10 to about 500, about 25 to about 300, about 50 to about 250, or about 100 to about 200, as measured according to ASTM 937. Examples of semi-solids can also include materials having a melting point or a drop melting point measured according to ASTM method D127 or a freezing point of about 40 ℃ to about 120 ℃, about 50 ℃ to about 100 ℃, about 50 ℃ to about 90 ℃, or about 60 ℃ to about 80 ℃ measured according to ASTM method D938. In preferred embodiments, the semi-solid may not comprise a stick of product or a significantly solid strip of solid material held within the dispensing container that retains its structural integrity and shape when applied to a surface to be treated.

As used herein, the term "particulate semi-solid dispersion" is an example of a dispersion in which the particles are dispersed in a semi-solid phase. Examples of particulate semi-solid dispersions include particles of hydrophilic active agents dispersed in petrolatum.

As used herein, the term "hydrophilic active agent particle" is a particle having the following characteristics: a) comprises an active agent, and b) is soluble in water, swells (volume and/or weight increase) upon contact with water, and/or releases the active agent upon contact with water. If the active agent is released, the active agent can be a gas, a liquid, or a solid dissolved in a liquid. In addition, the hydrophilic active agent particles may be insoluble in the hydrophobic phase. The hydrophilic active agent particles or semi-solid multi-phase oral composition may further comprise ingredients that are water soluble, water miscible, or combinations thereof, such as: water, water-soluble solvents, alcohols, acrylic polymers, polyalkylene glycols, humectants, glycerin, sorbitol, xylitol, butylene glycol, polyethylene glycol, and propylene glycol, and mixtures thereof. The hydrophilic active agent particles may also comprise water of hydration or a crystallization solvent. If these ingredients are added to or present in the hydrophilic active agent particles, the percentage of hydrophilic active agent particles in the composition is calculated by excluding these ingredients. If water-insoluble or water-immiscible fillers are added to the hydrophilic active agent particles or the semi-solid multi-phase oral composition, the percentage of hydrophilic active agent particles in the composition is calculated by excluding these fillers. In particular, the hydrophilic active agent particles may comprise a bleaching agent, an antimicrobial agent, and/or an anticaries agent.

As used herein, the term "active agent" is a benefit-providing component of a hydrophilic active agent particle. In particular, the active agent may include a bleaching agent, an antimicrobial agent, and/or an anticaries agent.

As used herein, the term "bleaching agent" is a component of bleaching in a bleach granule. For example, if urea peroxide (also known as urea hydrogen peroxide adduct) is used as the bleach particle, the hydrogen peroxide component of the urea peroxide particle is the bleach. Similarly, if a complex of hydrogen peroxide and polyvinylpyrrolidone (PVP) polymer is used as the bleach particle, the hydrogen peroxide component of the complex of hydrogen peroxide and polyvinylpyrrolidone (PVP) polymer is the bleach.

As used herein, the term "hydrophobic phase" refers to all components of the water-immiscible composition. In addition, the hydrophobic phase may be insoluble in water. In addition, the hydrophobic phase may also contain ingredients that are soluble, miscible or a combination thereof in the hydrophobic phase, such as a hydrocarbon solvent dissolved in the hydrophobic phase, polyethylene dissolved in the hydrophobic phase, microcrystalline wax dissolved in the hydrophobic phase, or a mixture thereof. In particular, the hydrophobic phase is a semi-solid. If water-insoluble or water-immiscible fillers are added to the hydrophilic active agent particles or the semi-solid multi-phase oral composition, the percentage of hydrophobic phase in the composition is calculated by including these fillers as part of the hydrophobic phase.

As used herein, the term "petrolatum" refers to a semi-solid mixture of hydrocarbons. Petrolatum may have a cone penetration consistency value of about 10 to about 500, about 25 to about 300, about 50 to about 250, or about 100 to about 200 measured according to ASTM method D937. Petrolatum may have a melting or dropping point measured according to ASTM method D127, or a freezing point of about 40 ℃ to about 120 ℃, about 50 ℃ to about 100 ℃, about 50 ℃ to about 90 ℃, or about 60 ℃ to about 80 ℃ measured according to ASTM method D938.

As used herein, the term "cone penetration consistency value" refers to the depth in tenths of a millimeter that a standard cone will penetrate a sample under fixed mass, time and temperature conditions. Cone penetration consistency values are measured according to ASTM method D937.

As used herein, the term "delivery vehicle" includes materials or appliances used to hold a semi-solid multi-phase oral composition against a tooth surface. Examples of delivery vehicles include strips or trays.

As used herein, the term "strip" includes material 1) whose longest dimension is generally longer than its width, and 2) whose width is generally greater than its thickness. The strip may be rectangular, arcuate, curved, semi-circular, have rounded corners, have slits cut therein, have notches cut therein, be curved into a three-dimensional shape, or a combination thereof. The strip may be solid, semi-solid, textured, malleable, flexible, deformable, permanently deformable, or a combination thereof. The strip may be made of a plastic sheet, including polyethylene or wax sheet. An example of a strip comprises a polyethylene sheet approximately 66mm long, 15mm wide and 0.0178mm thick. An example of a permanently deformable strip includes a sheet of poured wax approximately 66mm long, 15mm wide, and 0.4mm thick.

The semi-solid multi-phase oral compositions herein can be particulate semi-solid dispersions useful for topical application, particularly in the mouth. For example, the composition may be an oral care composition.

As used herein, the word "or," when used as a conjunction with two or more elements, is intended to include the elements described individually or in combination; for example, X or Y, refers to X or Y or both.

As used herein, the articles "a" and "an" are understood to mean one or more of the materials claimed or described, for example, "oral care compositions" or "bleaching agents".

As used herein, by "safe and effective amount" is meant an amount of a component that is high enough to significantly (definitively) alter the condition or effect to be treated to achieve the desired whitening efficacy, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical/dental judgment. The safe and effective amount of the component will depend upon the particular condition being treated, the age and physiological condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of the co-treatment, the particular form employed and the particular carrier in which the component is to be used.

As used herein, by "a period of time sufficient to achieve whitening" or "a period of time sufficient to achieve a desired effect of an active" is meant that the composition is used or worn by a participant, or that the participant is instructed to use or wear the composition for greater than about 10 seconds; or greater than about 1 minute, such as from about 2.5 minutes to about 12 hours (e.g., overnight treatment), or from about 3 minutes to about 180 minutes; or greater than about 5 minutes, such as about 5 minutes to about 60 minutes; or greater than about 10 minutes, such as from about 10 minutes to about 60 minutes; or each administration is from about 1 minute, 5 minutes, 10 minutes, 15 minutes to about 20 minutes, 30 minutes, 60 minutes, 120 minutes; or any other numerical range that is narrower and falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. Further, the treatment may be administered about 1,2, or 3 times a day to about 4,5, 6, or 7 times a day. The treatment may be applied for about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or about 7 days to about 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 21 days, or 28 days, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. Furthermore, the length of treatment to achieve a desired benefit (e.g., tooth whitening) can last for a specified period of time, which can be repeated, if desired, for example, from about one day to about six months, specifically from about one day to about 28 days, or from about 7 to about 28 days. The optimal duration and frequency of administration depends on the desired effect, the severity of all conditions to be treated, the health and age of the user and similar factors.

As used herein, the term "dispenser" refers to any pump, tube, or container suitable for dispensing an oral composition.

The units "μm" or "micron" as used herein refer to microns.

As used herein, the term "equivalent diameter" of a particle refers to the diameter of a sphere having the same volume as the particle.

All percentages and ratios used below are by weight (wt%) of the total composition unless otherwise indicated. Unless otherwise indicated, all percentages, ratios, and levels of ingredients referred to herein are based on the actual amount of the ingredient and do not include solvents, fillers, or other materials with which the ingredient may be used in commercially available products.

All measurements referred to herein are made at about 23 ℃ (i.e., room temperature) unless otherwise indicated.

The "active ingredients and other ingredients" useful herein may be classified or described herein according to their cosmetic and/or therapeutic benefits or their postulated mode of action or operation. It is to be understood, however, that in some instances, the actives and other ingredients useful in the present invention may provide more than one cosmetic and/or therapeutic benefit, or function or operate via more than one mode of action. Thus, classifications herein are made for the sake of convenience and are not intended to limit the ingredient to the particular stated function or activity listed.

As used herein, the term "tooth" refers to natural teeth as well as artificial teeth or dental prosthesis, and is to be construed as including one tooth or a plurality of teeth. As used herein, the term "tooth surface" refers to a natural tooth surface as well as a corresponding artificial tooth surface or denture surface.

The term "orally acceptable carrier" includes one or more compatible solid or liquid excipients or diluents suitable for use in the oral cavity. As used herein, by "compatible" is meant that the components of the composition are capable of being mixed but do not interact, which interaction can significantly reduce the stability and/or efficacy of the composition.

The term "about" means. + -. 10%.

Multi-phase oral compositions

A semi-solid multi-phase oral composition as disclosed herein comprises particles of a hydrophilic active agent dispersed in a hydrophobic phase. The semi-solid multi-phase oral composition as disclosed herein can be a semi-solid dispersion comprising hydrophilic active agent particles, such as hydrophilic bleach particles, dispersed in a hydrophobic phase.

For dispersions containing hydrophilic active agent particles, if a bleaching agent is used, the particle size of the hydrophilic active agent particles can be a factor in reducing oral/topical irritation, reducing tooth sensitivity, or increasing bleaching efficacy. Without being bound by theory, if the hydrophilic active agent particles are too large in size, large spots on the oral/topical/tooth surface exposed to high concentrations of active agent can result, which in turn can lead to oral/topical irritation and/or tooth sensitivity. For example, the number average equivalent diameter, surface area average equivalent diameter, or volume average equivalent diameter of the hydrophilic active agent particles may not exceed about 0.001 microns, 0.01 microns, 0.1 microns, 1 micron, 5 microns, 10 microns, 50 microns, 100 microns, 500 microns, or 1000 microns, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. In particular, the number average equivalent diameter, surface area average equivalent diameter, or volume average equivalent diameter of the hydrophilic active agent particles may be from about 0.001 microns to about 1000 microns, preferably from about 0.01 microns to about 1000 microns, more preferably from about 0.1 microns to about 100 microns, and most preferably from about 1 micron to about 100 microns, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. Compositions with high density of large hydrophilic active agent particles can lead to oral/topical irritation and/or tooth sensitivity. For example, the two-dimensional density of hydrophilic active agent particles having a cross-sectional area greater than about 1000 square microns, 3000 square microns, 10000 square microns, 20000 square microns, or 50000 square microns can be no more than about 100, 50, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4,3, 2, 1, or 0.5 per square centimeter two-dimensional plane, or any other range of values that is narrower and falls within such broader range of values, as such narrower range of values are all expressly written herein. In particular, the two-dimensional density of hydrophilic active agent particles having a cross-sectional area greater than about 10000 square microns can be no more than about 25, preferably no more than 10, more preferably no more than 5, and most preferably no more than 1, per square centimeter of the two-dimensional plane, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

The components and characteristics of the hydrophilic active agent particles and the hydrophobic phase are selected to allow the active agent to be easily released from the composition.

Without being bound by theory, it is believed that when the present invention, such as a semi-solid dispersion of hydrophilic bleach particles, is brought into contact with a tooth surface, the hydrophilic bleach particles migrate to the tooth surface, delivering the bleach to the hydrophilic biofilm of the surface. The net effect that is possible is that the tooth treatment effect only starts after contact with the tooth surface to be treated. This means that the hydrophilic active agent can be protected from the environment, being stabilized by the hydrophobic phase of the semi-solid multi-phase oral composition until use and potentially by the hydrophobic phase being in the form of a film or layer during use. Thus, the active effect can be applied to the tooth surface and the hydrophilic active, e.g., the bleaching agent can potentially shield the oral environment during use. Thereby enhancing and/or accelerating the efficacy of the semi-solid multi-phase oral composition.

Further without being bound by theory, the present invention may improve delivery of hydrophilic active agents to oral surfaces such as tooth or gum surfaces due to the partial hydrophobicity and partial hydrophilicity of the composition. Due to the driving force generated thereby, the hydrophilic active agent particles may be driven toward the tooth surface. Thus, even with surprisingly low total active agent content, increased speed and/or increased efficacy of the active agent can be achieved. Thus, at a given total overall concentration (such as less than 0.1 wt%, 1 wt%, or 5 wt% or less of active agent), the present invention can deliver a surprisingly high level of treatment efficacy, may require less application to achieve the same degree of efficacy, or may require a lower gel loading (milligrams of gel per unit area) to achieve the same degree of efficacy. Without being bound by theory, it is believed that part of the reason for the high efficacy achieved by the semi-solid multi-phase oral compositions of the present invention may be because they are self-adhesive or self-substantive to teeth and are resistant to being washed out in saliva or other liquids. This can maintain the active agent, such as a bleaching agent, in contact with oral surfaces (such as tooth surfaces) or in the oral cavity for extended periods of time, thereby achieving high efficacy. It is worth noting that, in general, substances that have an adhesive or affinity for the oral cavity are hydrophilic because the surfaces in the oral cavity are wet. It is also noteworthy that some product forms, particularly stick products, may require added affinity agents to adhere the composition to surfaces in the oral cavity. However, it has been surprisingly found that the semi-solid multi-phase oral composition of the invention and/or the hydrophobic phase of the invention is self-adhesive or self-substantive to surfaces in the oral cavity, such as tooth surfaces, even without added adhesive (e.g., hydrophilic particles that become tacky when activated by moisture, or hydrophilic liquids) or added substantivity agents. Achieving adhesion or substantivity without the use of added hydrophilic binders or hydrophilic substantivity agents is particularly useful as it can help make the semi-solid multi-phase oral composition resistant to being washed off in saliva or other liquids, resulting in higher efficacy. This is because achieving adhesion or affinity without the use of added hydrophilic binders or added hydrophilic affinity agents may allow us to increase the content of hydrophobic components (which resist washing away) and/or decrease the content of hydrophilic components (which are easy to wash away). Counterintuitively, this can help increase substantivity of the semi-solid multi-phase oral composition, resulting in high concentrations of active or bleaching agent in contact with oral surfaces (such as tooth surfaces) or in prolonged contact in the oral cavity, which in turn results in high efficacy. Furthermore, without being bound by theory, it is believed that the hydrophilic liquid may also leach from the semi-solid multi-phase oral composition and cause macroscopic separation of one or more components at temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition may be exposed during manufacture, filling, transport, or storage of the semi-solid multi-phase oral composition (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer. This is because hydrophilic liquids can be repelled by the hydrophobic phase and expelled from the semi-solid multi-phase oral composition. Thus, preferably, the semi-solid multi-phase oral composition of the invention and/or the hydrophobic phase of the invention are substantially free of added binders, preferably substantially free of added hydrophilic binders (e.g., hydrophilic particles that become tacky when activated by moisture) or added hydrophilic affinity agents, and more preferably substantially free of added hydrophilic liquid binders (e.g., glycerin). Preferably, the semi-solid multi-phase oral composition of the invention and/or the hydrophobic phase of the invention is self-adhesive or self-substantive to oral cavity surfaces such as teeth.

It is also noteworthy that some product forms, especially stick products, may require an added active substance releasing agent or an added peroxide releasing agent to improve the release of the active substance or peroxide trapped in the stick product. Generally, the active agent releasing agent or peroxide releasing agent is a hydrophilic water soluble or swellable polymer or hydrophilic liquid that can provide hydration pathways in the composition, allowing water to penetrate the composition and allow the active agent or peroxide to leach out. In certain embodiments, the added peroxide-releasing agent (such as sodium percarbonate) can help to break down the hydrophobic matrix due to microbubbles that can be generated when it comes into contact with water; and this destruction may enhance the release of whitening or active agents such as hydrogen peroxide. However, it has been surprisingly found that the semi-solid multi-phase oral compositions of the present invention are preferably self-releasing (e.g., they release active or peroxide even in the absence of added active release agents or added peroxide release agents). Achieving active or peroxide release without the use of added hydrophilic active release agents or added hydrophilic peroxide release agents is particularly useful as it can help make the semi-solid multi-phase oral composition resistant to being washed out in saliva or other liquids, resulting in high efficacy. This is because achieving active or peroxide release without the use of added hydrophilic active release agents or added hydrophilic peroxide release agents allows us to increase the content of hydrophobic components (which resist washing away) and/or to decrease the content of hydrophilic components (which are easy to wash away). Thus, preferably, the semi-solid multi-phase oral composition of the present invention is substantially free of added active agent releasing agents or added peroxide releasing agents, preferably substantially free of added hydrophilic active agent releasing agents or added hydrophilic peroxide releasing agents (e.g., water soluble or water swellable polymers, hydrophilic liquids or sodium percarbonate). In particular, the multiphase oral compositions of the present invention and/or the hydrophobic phase of the present invention are self-releasing (i.e., they release active or peroxide even in the absence of added active release agents or added peroxide release agents).

If the semi-solid multi-phase oral composition of the present invention comprises an added binder, an added hydrophilic liquid binder, an added hydrophilic affinity agent, an added hydrophilic active release agent, or an added hydrophilic peroxide release agent, it may be present in the range of about 0%, 0.1%, 0.2%, 0.4%, 1%, 2%, 3%, 4%, 5% to about 0%, 0.1%, 0.2%, 0.4%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, or any other broader range of values that is narrower and falls within such range of values, as if such narrower range of values were all expressly written herein; preferably less than about 20%, more preferably less than about 10%, even more preferably less than about 5%, or most preferably less than about 0.5%, by weight of the multi-phase oral composition.

In addition, the hydrophobic phase, when resistant to salivary dilution and salivary enzymes that can break down peroxide, can improve retention of the semi-solid multi-phase oral composition on the tooth surface. In addition, the hydrophobic phase does not dehydrate the teeth, thereby creating an outward flux of water formed by many hydrophilic compositions comprising hydrophilic binders such as polycarboxylic acids. Because the hydrophobic phase does not dehydrate teeth, even delivering surprisingly high levels of whitening or active efficacy can result in surprisingly low levels of tooth sensitivity.

In addition, the hydrophobic phase may also provide other advantages. For example, the hydrophobic phase represents a stable matrix of ingredients that are soluble in the hydrophobic phase. For example, many flavor ingredients commonly used in oral compositions are soluble in the hydrophobic phase. This means that any influence of the flavour ingredient by hydrophobic active agents (e.g. bleaching agents) in the oral composition can be avoided. Furthermore, without being bound by theory, during use of the oral composition at a dental surface, at least a portion of the hydrophobic phase may be positioned toward soft oral tissues, such as mucous membranes, thereby presenting to the oral cavity ingredients, such as flavor compounds, present in the hydrophobic phase. Furthermore, the hydrophobic phase may shield the hydrophobic active (such as a bleaching agent) from any influence of the oral cavity, such as dilution by saliva. The barrier effect may also be applied to the tooth surface itself, where the hydrophobic phase may provide greater hydration of the tooth surface.

The semi-solid multi-phase oral composition of the present invention can be a paste, a cream, a gel, a semi-solid, a viscoelastic gel, a sol, or any combination thereof.

Notably, stick products may be unsanitary for repeated use in the oral cavity due to potential contamination or biofilm build-up. Saliva or moisture may penetrate into the stick composition when the stick composition is used in the oral cavity, and this may degrade active agents, especially bleaching agents, such as peroxides; and this degradation can be further accelerated by enzymes present in the saliva. Furthermore, this degradation may be most pronounced at the end of the stick that comes into direct contact with saliva or moisture in the mouth, resulting in a decrease in efficacy the next time the stick is used. This "contact-degradation-contact" cycle can be repeated each time a stick product is used, resulting in a poor effect of most, if not all, applications after the first application. It is also noteworthy that the stick may require an added active substance releasing agent or an added peroxide releasing agent to improve the release of the active substance or peroxide trapped in the stick. Generally, the active agent releasing agent or peroxide releasing agent is a hydrophilic water soluble or swellable polymer or hydrophilic liquid that provides hydration pathways in the composition allowing water to penetrate the composition and allow the active agent or peroxide component to leach out. However, these channels may also allow more saliva to penetrate into the composition, which may accelerate the degradation of the active or peroxide.

Notably, multi-phase oral compositions in liquid form may exhibit macro-separation of one or more components due to differences in the density of the phases. In particular, compositions that are particles dispersed in one or more liquids may exhibit macro-separation of one or more components due to the difference in density of the particles compared to the liquid. In addition, multiphase oral compositions in liquid form may not be substantive and run down the teeth or off the delivery vehicle during application or during use.

Thus, stick products or liquid forms are less preferred or not preferred for the multi-phase oral compositions of the present invention. In contrast, the multi-phase oral composition of the present invention may preferably be a paste, cream, gel, semi-solid, or any combination thereof; and most preferably a semi-solid. Thus, the semi-solid multi-phase oral composition of the present invention is preferably substantially free of added wax as it may promote the formation of less preferred or less preferred stick products.

In preferred embodiments, the semi-solid multi-phase oral compositions of the present invention may be heterogeneous mixtures and/or heterogeneous dispersions.

Active agent

The compositions of the present invention comprise a safe and effective amount of one or more active agents. The solid hydrophilic active agent particles may contain a safe and effective amount of one or more active agents. Suitable active agents include any material that is generally considered safe for use in the oral cavity and provides a change in the overall appearance or health of the oral cavity. Other suitable oral care actives include one or more healing agents, anticalculus agents, fluoride ion sources, antimicrobial agents, remineralization agents, dentinal desensitizing agents, anesthetic agents, antifungal agents, cooling agents, anti-inflammatory agents, selective H-2 antagonists, anticaries agents, nutrientsErythritol, probiotics, resolvins (including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) anddocosapentaenoic acid(DPA), oleic acid, Resolvin D: RvD1(7S,8R, 17S-trihydroxy-DHA), RvD2(7S,16R, 17S-trihydroxy-DHA), RvD3(4S,7R, 17S-trihydroxy-DHA), RvD4(4S,5, 17S-trihydroxy-DHA), RvD5(7S, 17S-dihydroxy-DHA), and RvD6(4S, 17S-dihydroxy-DHA), and Resolvin E: RvE1(5S,12R, 18R-trihydroxy-EPA), 18S-Rv1(5S,12R, 18S-trihydroxy-EPA), RvE2(5S, 18R-dihydroxy-EPA) and RvE3(17R, 18R/S-dihydroxy-EPA)), tranexamic acid, glycine, retinol, amino acids such as histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine,TryptophanValine, alanine, asparagine, aspartic acid, glutamic acid, arginine, cysteine, glutamine, tyrosine, glycine, ornithine, proline and serine, peptides, amino acids and calcium salts of peptides, nicotinamide, human growth factor, and mixtures thereof. The oral care hydrophilic active agent particles can comprise the active at such a level that: when the active is used directly, the benefits sought by the wearer are promoted without damaging the oral surfaces to which it is applied. Examples of oral disorders addressed by these actives include, but are not limited to: alterations in tooth appearance and structure, stain removal, plaque removal, tartar removal, cavity prevention and treatment, redness and/or bleeding of the gums, mucosal damage, lesions, ulcers, aphthous ulcers, chilblain ulcers, dental abscesses, and elimination of oral malodor caused by the above and other causes (e.g., microbial proliferation). In preferred embodiments, the additional oral care active useful in the semi-solid multi-phase oral composition can be present in an amount of from about 0.01% to about 50%, from about 0.1% to about 20%, from about 0.5% to about 10%, or from about 1% to about 7%, by weight of the multi-phase oral composition, or any other range of values which is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

For example, the oral care active may be a healing agent that promotes or enhances healing or regeneration processes. Such healing agents may include hyaluronic acid or salt, glucosamine or salt, allantoin, curcumin, D-panthenol, niacinamide, ellagic acid, flavonoids (including fisetin, quercetin, luteolin, apigenin), vitamin E, ubiquinone, or mixtures thereof.

Additionally or alternatively, the oral care active may be one or more probiotics selected from Lactobacillus reuteri ATCC 55730; lactobacillus salivarius strain TI12711(LS 1); lactobacillus paracasei (Lactobacillus paracasei) ADP-1; streptococcus salivarius (Streptococcus salivarius) K12; bifidobacterium (Bifidobacterium) DN-173010; filtrate of Lactobacillus paracasei strain (pro-t-action)^TM) (ii) a Streptococcus oralis (s.oralis) KJ3, streptococcus rat (s.ratus) JH145, streptococcus uberis (s.uberis) KJ 2; lactobacillus reuteri mutants (Lactobacillus, reuteri mutants); lactobacillus salivarius LS 1; lactobacillus paracasei; lactobacillus paracasei ADP 1; streptococcus salivarius M18, K12 or BLISs K12 and BLISs M18; bacillus Amyloliquefaciens (Bacillus Amyloliquefaciens); bacillus Clausii (Bacillus Clausii); bacillus Coagulans (Bacillus Coagulans); bacillus Subtilis (Bacillus Subtilis); b, bacillus subtilis: e-300; bifidobacterium Animalis (Bifidobacterium Animalis); bifidobacterium B6; bifidobacterium Bifidum (Bifidobacterium Bifidum); bifidobacterium Breve (Bb-03); bifidobacterium DN-173010; bifidobacterium GBI 306068; bifidobacterium infantis (Bifidobacterium infantis); bifidobacterium Lactis (Bifidobacterium Lactis); bifidobacterium lactis Bb-12; bifidobacterium Longum (Bifidobacterium Longum); bifidobacterium Thermophilum (Bifidobacterium Thermophilum); enterococcus Faecalis (Enterococcus Faecalis); enterococcus Faecium (Enterococcus faecalis); enterococcus faecium NCIMB 10415; enterococcus (Enterococcus) LAB SF 68; lactobacillus reuteri ATCC55730 and ATCC PTA 5289; lactobacillus reuteri ATCC55730 and ATCC PTA 5289(10: 1); lactobacillus Acidophilus (Lactobacillus Acidophilus); lactobacillus acidophilus ATCC 4356 and bifidobacterium bifidum ATCC 29521; lactobacillus acidophilus; bifidobacterium longum; bifidobacterium bifidum; bifidobacterium lactis; lactobacillus brevis; lactobacillus Casei (Lactobacillus Casei) (subspecies Casi); lactobacillus casei field-replacing strain (Lac)tobacillus casei Shirota); lactobacillus fuscus (Lactobacillus conflussis); lactobacillus crispatus YIT 12319; lactobacillus Curvatus (Lactobacillus Curvatus); lactobacillus Delbrueckii subspecies bulgaricus (Lactobacillus Delbrueckii ssp. bulgaricus) PXN 39; lactobacillus Fermentum (Lactobacillus Fermentum); lactobacillus fermentum YIT 12320; lactobacillus Gasseri (Lactobacillus Gasseri); lactobacillus gasseri YIT 12321; lactobacillus Helveticus (Lactobacillus Helveticus); lactobacillus Johnsonii (Lactobacillus Johnsonii); lactobacillus sauerkraut (Lactobacillus Kimchii); lactobacillus Lactis (Lactobacillus Lactis) L1A; lactobacillus paracasei (Lpc 37); lactobacillus paracasei GMNL-33; lactobacillus Pentosus (Lactobacillus pentasus); lactobacillus plantarum (Lactobacillus plantarum); lactobacillus plantarum; lactobacillus plantarum (Lactobacillus Protectus); lactobacillus reuteri; lactobacillus reuteri ATCC 55730; lactobacillus reuteri SD2112(ATCC 55730); lactobacillus Rhamnosus (GG); lactobacillus rhamnosus GG; lactobacillus rhamnosus GG; lactobacillus rhamnosus LC 705; propionibacterium freudenreichii ssp; sheermanii (Shermanii) JS; lactobacillus rhamnosus L8020; lactobacillus rhamnosus LB 21; lactobacillus salivarius; lactobacillus salivarius WB 21; lactobacillus (Lactobacillus spongiogenes); lactococcus Lactis diacetyl subspecies (Lactococcus Lactis Ssp Diacetylactis); lactococcus Lactis subspecies Lactis (Lactococcus Lactis sp.lactis); pediococcus Acidilactici (Pediococcus Acidilactici); pediococcus Pentosaceus (Pediococcus pentasaceus); saccharomyces Boulardii (Saccharomyces Boulardii); saccharomyces Cerevisiae (Saccharomyces Cerevisiae); streptococcus uberis KJ2 sm; streptococcus oralis KJ3 sm; streptococcus rat JH 145; streptococcus mitis (Streptococcus mitis) YIT 12322; streptococcus oralis KJ 3; streptococcus rat JH 145; streptococcus salivarius (BLISs K12 or BLISs M18); streptococcus salivarius K12; streptococcus Thermophilus (Streptococcus Thermophilus); streptococcus uberis KJ 2; thermus thermophilus (Thermus thermophiles); weissella cibaria CMS 2; weissella civora CMS 3; and Weissella cibaria CMU.

Probiotics may be used in the semi-solid multi-phase oral compositions of the present invention to promote positive oral health effects, such as reduction of caries and plaque, promotion of gum health, improvement of breath, and promotion of whitening. The efficacy of probiotics in semi-solid multi-phase oral compositions can be determined, for example, by measuring one or more of the following: a reduction in the content of streptococcus salivarius; reduction of gingival crevicular fluid; reduction of periodontal pathogens (c.rectus and p.gingivitis) in subgingival plaque; a reduction in the number of yeasts; a decrease in prevalence of oral candida; reduced oral Volatile Sulfur Compound (VSC) content; and a reduction in TNF-alpha and IL-8 production. It is believed that one or more of the above positive oral health effects may be achieved by producing bacterial toxins that can remove or reduce certain types of bacteria in the oral cavity; furthermore, one or more of the above positive oral health effects may also be achieved by the bacteria producing one or more enzymes that inhibit the production of or dissolve/loosen biofilms or sticky deposits that may cause oral health problems.

Additionally or alternatively, a safe and effective amount of at least one anticalculus agent may be added to the compositions as disclosed herein. The amount can be from about 0.01% to about 40%, from about 0.1% to about 25%, from about 4.5% to about 20%, or from about 5% to about 15%, by weight of the multi-phase oral composition, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. The anticalculus agent may also be compatible with other components of the semi-solid multi-phase oral composition, in particular the active agent (e.g. whitening agent). The anticalculus agent is selected from polyphosphate esters and salts thereof; polyaminopropane sulfonic Acid (AMPS) and salts thereof; polyolefin sulfonates and salts thereof; polyvinyl phosphates and salts thereof; polyolefin phosphates and salts thereof; diphosphonates and salts thereof; phosphonoalkane carboxylic acids and salts thereof; polyphosphonates and salts thereof; polyvinyl phosphonates and salts thereof; polyolefin phosphonates and salts thereof; a polypeptide; and mixtures thereof, wherein the salt is typically an alkali metal salt. In particular, the anticalculus agents used in the semi-solid multi-phase oral compositions of the present invention also exhibit a stabilizing effect on hydrophilic actives (e.g., on bleaching agents such as pyrophosphates, polyphosphates, polyphosphonates, and mixtures thereof).

For example, the anticalculus agent may be a polyphosphate. Although some cyclic polyphosphate derivatives may be present, it is generally believed that polyphosphates comprise two or more phosphate molecules arranged predominantly in a linear configuration. The linear polyphosphate salt conforming to the formula (X PO)₃)_nWherein n is from about 2 to about 125, wherein n is preferably greater than 4, and X is, for example, sodium, potassium, and the like. For (X PO)₃)_nWhen n is at least 3, the polyphosphate is glassy in nature. The counter-ions of these phosphates may be alkali metals, alkaline earth metals, ammonium, C₂-C₆Mixtures of alkanolammonium and salts. Polyphosphates are generally used as their fully or partially neutralized water soluble alkali metal salts, such as potassium, sodium, ammonium salts, and mixtures thereof. Inorganic polyphosphates include alkali metal (e.g., sodium) tripolyphosphates, tetrapolyphosphates, dialkyl (e.g., disodium) dibasic acids, trialkyl (e.g., trisodium) monobasic acids, potassium hydrogen phosphate, sodium hydrogen phosphate, and alkali metal (e.g., sodium) hexametaphosphate, and mixtures thereof. Polyphosphates greater than tetrapolyphosphate typically occur as amorphous, glassy materials, such as those manufactured by FMC corporation, which are commercially known as Sodaphos (n. apprxeq.6), Hexaphos (n. apprxeq.13), Glass H (n. apprxeq.21), and mixtures thereof. If present, the compositions of the present invention will generally comprise from about 0.5% to about 20%, specifically from about 4% to about 15%, more specifically from about 6% to about 12%, by weight of the composition, of polyphosphate.

Pyrophosphate salts useful in the present compositions include alkali metal pyrophosphate salts, di-, tri-and mono-potassium or sodium pyrophosphate salts, di-alkali metal pyrophosphate salts, tetra-alkali metal pyrophosphate salts, and mixtures thereof. For example, the pyrophosphate is selected from: trisodium pyrophosphate, disodium dihydrogen pyrophosphate (Na)₂H₂P₂O₇) Dipotassium pyrophosphate, tetrasodium pyrophosphate (Na)₄P₂O₇) Tetrapotassium pyrophosphate (K)₄P₂O₇) And mixtures thereof, with tetrasodium pyrophosphate being preferred. In the present compositions, tetrasodium pyrophosphate may be in the anhydrous salt form or in the decahydrate formForms thereof, or any other species that is stable in solid form. The salt is in its solid particulate form, which may be in its crystalline and/or amorphous state, the particle size of the salt preferably being small enough to be aesthetically acceptable and readily soluble in use. The pyrophosphate salts may be present in the compositions of the present invention at a level of from about 1.5% to about 15%, specifically from about 2% to about 10%, and more specifically from about 3% to about 8%, by weight of the composition.

Phosphate sources include, but are not limited to, polyphosphates and pyrophosphates, which are described in more detail in Kirk and Othmer, Encyclopedia of Chemical Technology, fourth edition, Vol.18, Wiley-Interscience Publishers (1996), p.685 707.

Polyolefin phosphonates include those in which the olefin group contains 2 or more carbon atoms. The polyvinyl phosphonate includes polyvinyl phosphonic acid. Bisphosphonates and salts thereof include azacycloalkane-2, 2-diphosphonic acids and salts thereof, ions of azacycloalkane-2, 2-diphosphonic acids and salts thereof (e.g. those in which the alkane moiety has five, six or seven carbon atoms, the nitrogen atom being unsubstituted or bearing a lower alkyl substituent, such as methyl), azacyclohexane-2, 2-diphosphonic acid, azacyclopentane-2, 2-diphosphonic acid, N-methyl-azacyclopentane-2, 3-diphosphonic acid, EHDP (ethane hydroxy-1, 1-diphosphonic acid), AHP (azacyclopentane-2, 2-diphosphonic acid, a.k.a.1-azacycloheptadiene-2, 2-diphosphonic acid), ethane-1-amino-1, 1-diphosphonate, dichloromethane-diphosphonate, and the like. The acyl alkane carboxylic acids or alkali metal salts thereof include PPTA (phosphonopropane tricarboxylic acid), PBTA (phosphonobutane-1, 2, 4-tricarboxylic acid), each in the form of an acid or alkali metal salt.

Additionally or alternatively, antimicrobial antiplaque agents can also be present in the compositions of the present invention. Such agents may include, but are not limited to, triclosan, hop acids from hop extracts (such as hop alpha acids, including humulones, adhumulones, posthumulones, prohumulones, and combinations thereof, or hop beta acids, including lupulones, adlupulones, colupulones, and combinations thereof), 5-chloro-2- (2, 4-dichlorophenoxy) -phenol, such as described in The Merck Index 11 (1989) at page 1529 (catalog No. 9573), U.S. patent 3,506,720, and european patent application 0,251,591; chlorhexidine (Merck Index No. 2090), alexidine (Merck Index No. 222); hexetidine (Merck Index number 4624); sanguinarine (Merck Index No. 8320); benzalkonium chloride (Merck Index No. 1066); salicylanilide (Merck Index 8299); domiphen bromide (Merck Index No. 3411); cetylpyridinium chloride (CPC) (Merck Index No. 2024); tetradecylpyridine chloride (TPC); n-tetradecyl-4-ethylpyridine chloride (TDEPC); decadicaprylidine; delmopinol, octapinol and other piperidino derivatives; cocamidopropyl betaine, sodium cocamidoglutamate, sodium lauryl sarcosinate, GTF inhibitors, polyvinylpyrrolidone iododelmopinol, propolis, phthalic acid and its salts, monoperphthalic acid and its salts and esters, ascorbyl stearate, oleoyl sarcosine, alkyl sulfates. Additionally or alternatively, an effective antimicrobial amount of essential oils, herbal extracts, and combinations thereof can be present, such as citral, geranial, rosemary extract, tea extract, magnolia extract, eucalyptol geraniol, carvacrol, citral, sabinol, catechol, methyl salicylate, epigallocatechin gallate, epigallocatechin, gallic acid, miswak (miswak) extract, sea buckthorn extract, and combinations of menthol, eucalyptol, thymol, and methyl salicylate; antimicrobial metals and salts thereof; such as those that provide zinc ions, stannous ions, copper ions, and/or mixtures thereof; biguanides, or phenols; antibiotics such as wolgermantine, amoxicillin, tetracycline, doxycycline, minocycline, and metronidazole; and analogs and salts of the above antimicrobial antiplaque agents and/or antifungal agents, such as those used to treat candida albicans. These agents, if present, are generally present in a safe and effective amount, for example, from about 0.1% to about 5% by weight of the composition of the present invention.

The compositions of the present invention may contain a safe and effective amount of an anticaries agent, and mixtures thereof. The anticariogenic agent is selected from fluoride, sodium fluoride, potassium fluoride, titanium fluoride, hydrofluoric acid, amine fluoride, sodium monofluorophosphate, ammonium fluoride, stannous chloride, stannous gluconate, copper salt, and mixtures thereof,Copper chloride, copper glycinate, zinc chloride, zinc lactate, zinc citrate, zinc phosphate, sodium iodide, potassium iodide, calcium chloride, calcium lactate, calcium phosphate, hydroxyapatite, fluorapatite, amorphous calcium phosphate, crystalline calcium phosphate, sodium bicarbonate, sodium carbonate, calcium carbonate, oxalic acid, dipotassium oxalate, sodium potassium oxalate, casein phosphopeptide-coated hydroxyapatite, calcium phosphate-coated calcium phosphate, calcium phosphate₂、CaO、Na₂O、P₂O₅、CaF₂、B₂O₃、K₂O, MgO, such as those disclosed in US 5,735,942. When present, the ready-to-use composition, when used with a composition as disclosed herein, provides from about 50ppm to 10,000ppm, preferably from about 100ppm to 3000ppm, of fluoride ion in the composition in contact with the tooth surface.

Hydrophilic active agent particles

The semi-solid multi-phase oral compositions of the present invention comprise a safe and effective amount of particles of a hydrophilic active agent. The hydrophilic active agent particles may comprise bleach or hydrophilic bleach particles. For example, the maximum amount of hydrophilic active agent particles can be about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.095%, 0.099995%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 47.5%, or 50% by weight of the multi-phase oral composition, or any other range of values that is narrower and falls within such broader range of values, as such narrower ranges of values are all expressly written herein.

It has been surprisingly found that the solubility of hydrophilic active agent particles in water, the ability to swell upon contact with water, or the ability to release the active agent upon contact with water affects the efficacy of the composition. Specifically, at least about 20 parts by weight, 25 parts by weight, 30 parts by weight, 40 parts by weight, 50 parts by weight, 60 parts by weight, 70 parts by weight, or 80 parts by weight of the hydrophilic active agent particles are dissolved in about 100 parts by weight of water, or the hydrophilic active agent particles swell at least about 20%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% when contacted with water. Without being bound by theory, it is surprising that the amount of water that can hydrate the hydrophilic active agent particles and release the active ingredient on the buccal surface of the maxillary anterior teeth is low compared to the rest of the oral cavity. This is particularly important because the buccal surfaces of the maxillary anterior teeth are those most visible when smiling. Thus, the solubility of the hydrophilic active agent particles in water, their ability to swell upon contact with water, or their ability to release the active agent upon contact with water, may disproportionately affect the efficacy of the composition on the "smiling teeth" (the buccal surface of the maxillary anterior teeth).

Examples of hydrophilic active agent particles include hydrophilic bleach particles such as urea peroxide (also known as urea hydrogen peroxide, or urea hydrogen peroxide adducts), and complexes of hydrogen peroxide with polyvinylpyrrolidone (PVP) polymers (also known as peroxidone), and mixtures thereof.

Examples of hydrophilic bleach particles include providing a bleaching effect, stain removal effect, stain altering effect, or any other effect that alters or whitens the color of teeth. For example, the hydrophilic bleach particle comprises a source of peroxide radicals. Additionally or alternatively, the hydrophilic bleach particle can include peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulfates, compounds that form the foregoing in situ, and combinations thereof. Examples of peroxide compounds may include urea peroxide, calcium peroxide, urea hydrogen peroxide, and mixtures thereof. Examples of the metal chlorite may include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, potassium chlorite, and mixtures thereof. Examples of hydrophilic bleach particles may include hypochlorites (such as metal hypochlorites). Examples of persulfates may include salts of peroxymonosulfates, peroxydisulfates, and mixtures thereof. Examples of persulfates, perborates, percarbonates, and hypochlorites include the corresponding salts of sodium, calcium, potassium, and other metals.

Additionally or alternatively, the hydrophilic active agent particle may be about 0.001%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.095%, 0.099995%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 47.5% to about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.095%, 0.099995%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.07%, 0.9%, 3%, 4%, 5%, 10%, 5%, 9%, 10%, 5%, 10%, 5%, 9%, 5%, 10%, 5%, 9%, 5%, 10%, 5%, or 47.5% by weight of the multi-phase oral composition, 45%, 47.5%, or 50%, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

Specifically, the hydrophilic active agent particle content can be less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.099995%, 0.095%, or 0.09% by weight of the multi-phase oral composition, more specifically less than 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% by weight of the multi-phase oral composition, or from about 0.1% to about 0.9%, or from about 0.2% to about 0.8%, or from about 0.3% to about 0.7% by weight of the multi-phase oral composition, or any other numerical range that is narrower and falls within such broader numerical range, as such narrower numerical ranges are all expressly written herein. Alternatively, the hydrophilic active agent particles can be from about 0.6% to about 10%, or from about 0.6% to about 6%, or from about 1% to about 5%, or from about 1% to about 3%, by weight of the multi-phase oral composition, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

The level of hydrophilic bleach particle may be less than 0.1% by weight of the multi-phase oral composition, and in more preferred embodiments less than about 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, or 0.001% by weight of the multi-phase oral composition, or from about 0.01% to about 0.099995%, from about 0.01% to about 0.095%, or from about 0.05% to about 0.09% by weight of the multi-phase oral composition, or any other numerical range narrower and falling within such broader numerical range, as if such narrower numerical ranges were all expressly written herein, available oxygen or chlorine, respectively, provided as bleaching stains by the molecule. Surprisingly, the hydrophilic active agent particles are significantly effective even at low levels in multi-phase oral compositions as disclosed herein, which are in the form of a particulate semi-solid dispersion.

For example, the maximum amount of active agent can be about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.095%, 0.099995%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 47.5%, or 50% by weight of the multi-phase oral composition, or any other range of values that is narrower and falls within such broader range of values, as such narrower ranges of values are all expressly written herein.

Additionally or alternatively, the active agent can be about 0.001%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.095%, 0.099995%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 47.5% to about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.095%, 0.099995%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.08%, 0.09%, 0.095%, 5%, 35%, 5%, 9%, 0.0.9%, 9%, 5%, 9%, 5%, or 5%, or any other numerical range that is narrower and falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

Specifically, the active agent content can be less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.099995%, 0.095%, or 0.09% by weight of the multi-phase oral composition, more specifically less than 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% by weight of the multi-phase oral composition, or preferably from about 0.1% to about 0.9%, more preferably from about 0.2% to about 0.8%, more preferably from about 0.3% to about 0.7% by weight of the multi-phase oral composition, or any other numerical range that is narrower and falls within such broader numerical range, as such numerical ranges are all expressly written herein.

Concentration ratio of hydrogen peroxide

In a preferred embodiment, the hydrophilic active agent particles, such as hydrophilic bleach particles, deliver hydrogen peroxide by being an adduct or complex of hydrogen peroxide or a precursor to hydrogen peroxide. Thus, they achieve a high ratio of the weight percent concentration of hydrogen peroxide present in the hydrophilic bleach particle to the weight percent concentration of hydrogen peroxide present in the overall semi-solid multi-phase oral composition. This is caused by the combination of a high weight percent concentration of hydrogen peroxide present in the hydrophilic bleach particle and a relatively low weight percent concentration of hydrogen peroxide present in the overall semi-solid multi-phase oral composition.

Without being bound by theory, in embodiments of the present invention comprising hydrogen peroxide, this surprising combination of seemingly contradictory parameters utilizes a high driving force to deliver hydrogen peroxide to the tooth surface, even when the overall concentration or amount of hydrogen peroxide delivered to the tooth surface is low. Thus, a high driving force achieves surprisingly high levels of bleaching efficacy and/or bleaching speed; a low overall concentration or low level of bleaching agent delivered to the tooth surface at the same time may contribute to reduced tooth sensitivity.

Additionally or alternatively, the ratio of the weight percent concentration of hydrogen peroxide present in the hydrophilic bleach particles to the weight percent concentration of hydrogen peroxide present in the overall semi-solid multi-phase oral composition can be about 50000, 35000, 20000, 17500, 10000, 5000, 3500, 2000, 1750, 1160, 1000, 875, 700, 580, 500, 430, 400, 380, 350, 200, 175, 111, 110, 105, 100, 90, 80, 70, 60, 50, 40, 30, 20, 15, 10, or 5 to about 50000, 35000, 20000, 17500, 10000, 5000, 3500, 2000, 1750, 1160, 1000, 875, 700, 580, 500, 430, 400, 380, 350, 200, 175, 111, 110, 105, 100, 90, 80, 70, 60, 50, 40, 30, 20, 15, 10, or 5, or any other numerical range that is narrower and falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

Additionally or alternatively, the ratio of the weight percent concentration of hydrogen peroxide present in the hydrophilic bleach particles to the weight percent concentration of hydrogen peroxide present in the overall semi-solid multi-phase oral composition can be at least or in excess of about 50000, 35000, 20000, 17500, 10000, 5000, 3500, 2000, 1750, 1160, 1000, 875, 700, 580, 500, 430, 400, 380, 350, 200, 175, 110, 105, 100, 90, 80, 70, 60, 50, 40, 30, 20, 15, 10, or 5, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

The hydrophilic active agents of the present invention may be stabilized against degradation by the shielding effect of the hydrophobic phase.

Optional stabilizers for active agents

The semi-solid multi-phase oral composition of the present invention may comprise a stabilizer for the active agent. Active agents including bleaching agents may further be directed against those resulting from semi-solid multi-phase oral compositionsAnd (4) degradation is stable. Thus, stabilizers may be added to the compositions of the present invention. Suitable stabilizers are, for example, orthophosphoric acid, phosphates such as sodium hydrogen phosphate, pyrophosphates, organic phosphonates, ethylene diamine tetraacetic acid, ethylenediamine-N, N '-diacetic acid, ethylenediamine-N, N' -disuccinic acid, potassium stannate, sodium stannate, tin salts, zinc salts, salicylic acid, 1-hydroxyethylidene-1, 1-diphosphonic acid, and combinations thereof. In particular, stabilizers may be used which exhibit additional oral care effects such as anti-tartar effects, which results from: phosphates such as pyrophosphate, tripolyphosphate, hexametaphosphate, phytic acid, PO₃(PO2)_nSalts of PO3 (where n ═ 2-30), phosphoric acid, gantrez, zinc salts (including zinc citrate, zinc lactate, zinc chloride, zinc phosphate, zinc oxide), enzymes such as dextranase, xylanase, protease, peroxides (including hydrogen peroxide, urea peroxide, and sodium percarbonate), phosphonates such as diphosphonates, chelators such as EDTA, sodium calcium EDTA, citrates, citric acid, oxalic acid, oxalates, polymers (such as those disclosed in U.S. patent application 16/216,329), PVP, polyacrylic acid (acrylic acid polymers), polyacrylates, stannous salts, tin salts. The stabilizing agent may be present in the semi-solid multi-phase oral composition of the present invention in an amount of from about 0.0000001%, 0.000001%, or 0.00001% to about 0.00001%, 0.0001%, or 0.01%, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. In particular, the stabilizing agent may be present in the semi-solid multi-phase oral composition of the present invention in an amount of from about 0.0001% or 0.01% to about 0.01%, 0.1% or about 1%, or any other range of values which is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

The stabilizer may also include a chelating agent. The chelating agent may be a copper, iron and/or manganese chelating agent, or a mixture thereof. Suitable chelating agents may be selected from: diethylene triamine pentaacetate, diethylene triamine penta (methylphosphonic acid), ethylenediamine-N 'N' -disuccinic acid, ethylene diamineTetraacetate salts, ethylene diamine tetra (methylene phosphonic acid), hydroxyethane di (methylene phosphonic acid), and any combination thereof. Suitable chelating agents may be selected from ethylenediamine-N' -disuccinic acid (EDDS), hydroxyethane diphosphonic acid (HEDP) or mixtures thereof. The stabilizer may comprise ethylenediamine-N' -disuccinic acid or salts thereof. ethylenediamine-N' -disuccinic acid can be in the form of the S, S enantiomer. The composition may comprise 4, 5-dihydroxyisophthalate disodium salt, glutamic acid-N, N-diacetic acid (GLDA) and/or a salt thereof, 2-hydroxypyridine-1-oxide, Trilon P from BASF (Ludwigshafen, Germany)^TM. Suitable chelating agents may also be calcium carbonate crystal growth inhibitors. Suitable calcium carbonate crystal growth inhibitors may be selected from: 1-hydroxyethane diphosphonic acid (HEDP) and salts thereof; n, N-dicarboxymethyl-2-aminopentane-1, 5-dioic acid or its salt; 2-phosphonobutane-1, 2, 4-tricarboxylic acid and salts thereof; and any combination thereof.

The stabilizer may comprise calcium carbonate crystal growth inhibitors such as 1-hydroxyethane diphosphonic acid (HEDP); n, N-dicarboxymethyl-2-aminopentane-1, 5-dioic acid; 2-phosphonobutane-1, 2, 4-tricarboxylic acid; and salts thereof; and any combination thereof.

The stabilizer may comprise a hydroximic acid chelating agent. By "hydroxamic acid" herein is meant a hydroxamic acid or corresponding salt, for example cocoa hydroxamic acid (Axis House RK 853).

Hydrophobic phase

The present invention comprises a safe and effective amount of a hydrophobic phase. For example, the semi-solid multi-phase oral composition of the present invention comprises a hydrophobic phase, wherein the hydrophobic phase may be at least or greater than about 550%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, or 99.5%, by weight of the multi-phase oral composition, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. In particular, the hydrophobic phase may be at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, or 99.5%, by weight of the multi-phase oral composition, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. Preferably, the semi-solid multi-phase oral composition of the present invention comprises a hydrophobic phase, wherein the hydrophobic phase may be more than about 50% by weight of the multi-phase oral composition.

Furthermore, the hydrophobic phase may be present in a major proportion relative to the hydrophilic active agent particles present in the semi-solid multi-phase oral composition. As used herein, "major proportion" means that the weight percentage of the hydrophobic phase of the semi-solid multi-phase oral composition exceeds the weight percentage of the hydrophilic active agent particles of the semi-solid multi-phase oral composition.

The hydrophobic phase may be inert or at least partially inert. The hydrophobic phase may interact with other ingredients in the semi-solid multi-phase oral composition comprising the active agent, such as flavoring agents or thickening agents, but in certain embodiments does not interact or interacts only very little.

Suitable hydrophobic phases for use in the compositions as disclosed herein can have an octanol/water partition coefficient (log P) of greater than about 2,3, 4,5, or greater than about 5.5_ow). Specifically, the hydrophobic phase exhibits a log P of greater than about 6, or any other range of values that is narrower and falls within such broader range of values_owAs such, narrower numerical ranges are all expressly written herein.

Without being bound by theory, the melting point, drop melting point, or freezing point of the hydrophobic phase may be a factor in ensuring that the composition has the following characteristics: 1) is substantive and does not run down the teeth or run off the delivery vehicle during application or use, 2) inhibits macroscopic separation of one or more components at temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition can be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer, or 3) releases an effective amount of an active agent during use. In particular, if the melting, drop melting or freezing point of the hydrophobic phase is too low, the semi-solid multi-phase oral composition may not be substantive and run down the teeth or out of the delivery vehicle during application or during use; or the semi-solid multi-phase oral composition can exhibit macroscopic separation of one or more components at temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition can be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer. In contrast, if the melting, dripping or freezing point of the hydrophobic phase is too high, the semi-solid multi-phase oral composition may not release an effective amount of the active agent during use. In particular, the melting, dropping, or freezing point of a suitable hydrophobic phase may be in the range of about 40 ℃ to about 120 ℃, about 50 ℃ to about 100 ℃, about 50 ℃ to about 90 ℃, about 60 ℃ to about 80 ℃, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. Additionally or alternatively, the melting or dropping point of the hydrophobic phase as measured according to ASTM method D127 or the freezing point as measured according to ASTM method D938 can be about 120 ℃, 100 ℃, 90 ℃, 85 ℃, 80 ℃, 75 ℃, 70 ℃, 60 ℃,50 ℃, 40 ℃, or 30 ℃ to about 100 ℃, 90 ℃, 85 ℃, 80 ℃, 75 ℃, 70 ℃, 60 ℃,50 ℃, 40 ℃,30 ℃, or 25 ℃, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

Without being bound by theory, the cone penetration consistency value of the hydrophobic phase or the semi-solid multi-phase oral composition may be a factor in ensuring that the semi-solid multi-phase oral composition has the following characteristics: 1) is substantive and does not run down the teeth or run off the delivery vehicle during application or use, 2) inhibits macroscopic separation of one or more components at temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition can be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer, or 3) releases an effective amount of an active agent during use. In particular, if the cone penetration consistency value of the hydrophobic phase or semi-solid multi-phase oral composition is too high, the semi-solid multi-phase oral composition may not be substantive and run down the teeth or out of the delivery vehicle during application or during use; or the semi-solid multi-phase oral composition can exhibit macroscopic separation of one or more components at temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition can be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer. In contrast, if the cone penetration value of the hydrophobic phase or semi-solid multi-phase oral composition is too low, the semi-solid multi-phase oral composition may not release an effective amount of active agent during use. It is worth noting that, in general: 1) hydrophobic phases with low cone penetration consistency values tend to form stick products, especially when combined with active or bleach-containing powder ingredients that are milled or manufactured to minimize particle size, e.g., by micronization, 2) wax-rich hydrophobic phases tend to have low cone penetration consistency values, 3) stick products tend to have low cone penetration consistency values, 4) hydrophobic phases with low cone penetration consistency values (which tend to form stick products) may also inhibit release of bleach or active, and 5) stick products (which tend to have low cone penetration consistency values) may also inhibit release of bleach or active. It is also noteworthy that multi-phase oral compositions having low cone penetration consistency values or those whose hydrophobic phase has low cone penetration consistency values may have difficulty or inability to manually dispense appropriate doses of the multi-phase oral composition from a tube. Thus, for example, the cone penetration value of a hydrophobic phase or semi-solid multi-phase oral composition may optimally be in the range of from about 10 to about 500, from about 25 to about 300, from about 50 to about 250, or from about 100 to about 200, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein and measured according to the methods specified herein.

The cone penetration consistency value of the hydrophobic phase or semi-solid multi-phase oral composition can be from about 10, 25, 50, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 to about 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 300, 400, 500, 600, or 620, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein and as measured according to the methods specified herein.

Without being bound by theory, macro-segregation of one or more components at temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition may be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer may compromise efficacy, safety, comfort, use experience, concentration of active or bleaching agent at the tooth surface over time, activity or bleaching efficacy, or compatibility between ingredients. For example, compositions that exhibit macroscopic separation at temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which a hydrophilic active agent particle or active agent-containing phase can be exposed during manufacture, filling, transport, or storage of a semi-solid multi-phase oral composition (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer can result in a concentration of the active agent that varies from one dose to another and/or over time. This can compromise efficacy, comfort or use experience at certain doses (e.g., via oral irritation or tooth sensitivity); and this may vary from dose to dose and/or over time. In particular, if, for example, a substantial portion of the hydrophilic active agent particles have macroscopically separated into one phase, a disproportionately rich dosage in that phase may result in oral irritation or tooth sensitivity when it comes into contact with the oral soft tissue or teeth. In contrast, if, for example, a substantial portion of the hydrophobic phase has been macroscopically separated into one phase, a disproportionately rich dose of that phase may have reduced efficacy. Both of these cases are undesirable because one case leads to higher discomfort and the other case leads to lower efficacy.

Macroscopic separation of one or more components at temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition can be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) and prior to use by a consumer, as measured according to methods specified herein, can be about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 50% to about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 50%, or any other numerical range that is narrower and falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. Additionally or alternatively, the macroscopic separation after storage of one or more components at 23 ℃ +/-2 ℃ for 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months, measured according to the methods specified herein, can be about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 50% to about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 50%, or any other numerical range that is narrower and falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. Additionally or alternatively, the macro-segregation of one or more components after 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months storage at 23 ℃ +/-2 ℃ measured according to the methods specified herein can be no greater than or less than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 50%.

Specifically, the macroscopic separation of one or more components after storage at 23 ℃ +/-2 ℃ for 2 days measured according to the methods specified herein can be about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 50% to about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 50%, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. Additionally or alternatively, the macro-separation of one or more components after storage at 23 ℃ +/-2 ℃ for 2 days, measured according to the methods specified herein, can be no greater than or less than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 50%.

Method of measuring percent macro-separation of one or more components of a multi-phase oral composition

1. 50ml of the multi-phase oral composition was transferred to a 50ml polypropylene conical tube (Falcon brand catalog number REF 352098, Corning Science, Tamaulipas, Mexico). If the multi-phase oral composition exhibits macro-separation of one or more components prior to transfer into the tapered tube, the multi-phase oral composition is agitated in a Speedmixer ("Max 300Long Cup Translucent", product number 501218 t, available from Flacktek Inc., Landrum, SC) (e.g., for 2 minutes at 800 RPM) and transferred into the tapered tube, which then exhibits macro-separation of one or more components. If the multi-phase oral composition has macro-bubbles or voids: 1) tapping the conical tube on a hard surface until it is free of macro bubbles or voids, or 2) using a different method to transfer the multi-phase oral composition into the conical tube such that it is substantially free of macro bubbles or voids. The cap is screwed onto the conical tube. A total of three cones were repeated.

2. All three tapered tubes are positioned in a vertical orientation (e.g., in a test tube rack) with the tapered ends at the bottom and the top cover at the top.

3. All three conical tubes are kept undisturbed in a vertical position in the room or chamber, wherein the air is kept at said temperature (e.g. -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃ or 60 ℃) for a period of time during which the macro-separation will be measured.

4. At the end of the period of time (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) after which the macro-separation will be measured after the vertical position is maintained, the volume of macro-separated material on the bottom of the conical tube is measured (via the scale on the conical tube). If the volume of material macroscopically separated on the bottom of the conical tube is greater than 25ml, the volume of material macroscopically separated on the top of the conical tube is measured.

Calculate the average volume of material macroscopically separated in all three tubes.

The volume fluctuation of the macroscopically separated material from tube to tube was evaluated as follows: the volume of material separated in each tube must be within +/-2.5ml of the mean. If the volume of material separated in any one or more of the tubes is outside of +/-2.5ml of the mean: this is an indication of sample-to-sample fluctuations potentially due to macro-separation of one or more components prior to transfer into the conical tube, and the method needs to be repeated from step 1 to minimize sample-to-sample fluctuations.

5. Percent macro separation was calculated as: 100 × (average volume of macro-separated material measured and calculated in step 4 divided by 50 ml).

In order to validate the above method, it is necessary to measure and confirm that the macro-separation percentage of one or more components of the validation composition specified below is between 6% and 10%.

Validation composition for a method of measuring percent macro-separation	(wt%)
		35% aqueous solution H2O2 1	1.43
Sterile filtered water2	4.24
		Aerosol OT3	1.00
Mineral oil4	93.33

¹Super cosmetic grade from Solvay, Houston, Texas

²Calbiochem catalog No. 4.86505.1000, available from EMD Millipore Corporation, Billerica, Massachusetts

³Aerosol OT-100 available from Cytec Industries, Princeton, NJ

⁴Kaydol grade paraffin oil, available from Sonneborn LLC, Petroli, Pennsylvania

Procedure for preparing a validation composition for a method for measuring percent macro-separation

A 175 gram batch of the validation composition was prepared by the following procedure:

a) 1.75 grams of Aerosol OT and 163.33 grams of mineral oil were weighed into a Speedmixer container ("Max 300Long Cup Translucent", product number 501218 t, available from Flacktek Inc., Landrum, SC).

b) The mixture was heated in an oven and stirred to dissolve the Aerosol OT in the mineral oil. This can be done by heating in an oven at 60 ℃ to 70 ℃ and stirring for 2 minutes at 800RPM by hand vortexing or in a Speedmixer and repeated until Aerosol OT is dissolved in mineral oil.

c) In a separate plastic container, 42.4 grams of sterile filtered water and 14.3 grams of 35% aqueous H2O2 solution were weighed and vortexed together. 9.92 g of this diluted solution of H2O2 in water was weighed into a Speedmixer container.

d) The contents of the Speedmixer vessel were stirred in the Speedmixer at 800RPM for 2 minutes. The wall of the vessel was then scraped with a plastic spatula and the contents were again stirred at 800RPM for 2 minutes. The walls of the container were then scraped with a plastic spatula and the contents were stirred a third time at 800RPM for 2 minutes.

Without being bound by theory, for a multi-phase oral composition comprising peroxide, the average residual peroxide concentration of the multi-phase oral composition may be such that the multi-phase oral composition: 1) is substantive and does not wash off during use; and 2) still release an effective amount of the active agent during use. In particular, if the average residual peroxide concentration of the multi-phase oral composition on the tooth surface is too low, the multi-phase oral composition may not be substantive and rinse off during use, or an effective amount of active agent is not released during use. The average residual peroxide concentration of the multi-phase oral composition applied to the teeth, as measured using the procedures specified herein, may be from about 1,2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, or 225 to about 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, or 225, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. In particular, the average residual peroxide concentration of the multi-phase oral composition applied to the teeth, as measured using the procedures specified herein, can be from about 1 to about 200, preferably from about 10 to about 200, more preferably from about 50 to about 200, and most preferably from about 100 to about 200, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

For measuring spread on teethMethod for averaging residual peroxide concentration of composition

1. Disks (7.5mm to 7.8mm diameter x 1.2mm to 1.3mm thickness) were cut from the anterior surface of human incisors. The front surface was left intact, but the back surface that had been cut from the teeth was flattened using sandpaper. The dental tray is soaked in 15ml to 20ml of water meeting USP specifications in a glass vial for at least 24 hours. The tray was removed from the water and placed on a fresh paper towel with its front surface facing up.

2. 290 to 310 grams of water meeting USP specifications were weighed into cylindrical plastic containers having screw caps of 82 to 107mm diameter x 106 to 108mm height ("Max 200Long Cup Translucent", product No. 501220 t from flaktek, Landrum, SC). The water in the container with the cap screwed on was preheated in a convection oven at an air temperature of 33C to 35C for at least 12 hours.

3. From 0.04 grams to 0.06 grams of the composition was weighed onto the tip of a disposable Lip Gloss Applicator ("Flocked Doe Foot Lip Gloss Applicator" made from nylon and polystyrene, available from Qosmedix inc., ronkonkokma, NY, catalog number 74111).

4. The composition is transferred to the tray by first rolling the lip gloss applicator loaded with the composition over the front surface of the tray and then fanning out toward the annular edge.

5. Pick up the dental plate with forceps. Ensuring that the forceps contact only the rounded edges of the tray and not the tray surface to which the composition is applied. The plastic container was tilted and the dental plate was gently placed into the water on the cylindrical wall of the container, which was attached to the flat bottom. Ensuring that the treated surface of the tray faces upwardly away from the cylindrical wall of the container.

6. The cylindrical vessel was placed on a roller stirrer (model TSRT9, available from Techni as VWR, Batavia, IL, catalog number 89132-. The roller agitator was turned on-this gently rotated the container at 12 to 14 RPM. The crankset should continue to remain immersed in the water and the treated surface should continue to face away from the rotating cylindrical wall. This rotational movement causes the water to flow gently over the dental tray similar to the gentle movement of saliva and other liquids over the teeth in the mouth.

7. After turning off the roller agitator for 58 to 62 minutes, fresh peroxide test strips (supplied by EMD Millipore Corporation, Billerica, MA, supplier number: 1.16974.0001; available from VWR, Batavia, IL, Cat. No. EM1.16974.0001) were removed and a timer was started.

8. Digital images of the peroxide test strips were taken. Apparatus and system configurations for taking digital images of test strips are specified herein.

9. The tray was removed from the water using forceps. As previously described, it is ensured that the forceps contact only the rounded edges of the tray and not the tray surface on which the composition is applied. The dental tray was placed on the fingertips with gloves. Ensure that the surface of the tray with the composition applied thereon is facing up away from the gloved fingertips.

10. The peroxide test strip was placed on the dental tray such that one of the reaction zones contacted the surface of the dental tray with residual composition. The peroxide test strip was clamped between thumb and forefinger against the dental tray and firm finger pressure was applied between thumb and forefinger for 2 to 3 seconds.

11. The peroxide test strip was moved to a clean area of the paper towel. Filter paper (Whatman grade 1 quality filter paper standard grade, circular, 90mm, supplier number 1001-090; available from VWR, Batavia, IL, catalog number 28450-081) was placed on top of the test strips. Finger pressure was applied on top of the filter paper. Pulling the peroxide test strip off the filter paper in a single formation (while maintaining finger pressure on the filter paper) causes excess gel to rub off on the filter paper and paper towel. Ensure that the reaction zone does not fall off the peroxide test strip.

12. Digital images of the peroxide test strips were taken. Apparatus and system configurations for taking digital images of test strips are specified herein.

13. Steps 7 to 12 must be completed within 3 minutes on a timer.

14. Steps 1 to 13 are repeated for a minimum of twelve teeth.

15. The average and standard deviation of RED intensity of the bars of the Munsell N8 matte color chip attached to the scaffold, used as a built-in Munsell N8 reference within each image, were measured using Adobe Photoshop CS4 with the procedure specified herein. The average RED intensity of the built-in Munsell N8 reference within each image should be 204 to 212 and the standard deviation should not exceed 3.

16. The average of the RED intensity of the reaction zone over all peroxide test strips at baseline (before pressing against the dental disc) was measured using Adobe Photoshop CS4 with the procedure specified herein.

17. The average of the RED intensity of the reaction zone on all peroxide test strips after pressing against the dental disc was measured using Adobe Photoshop CS4 with the procedure specified herein.

18. The average residual peroxide concentration of the composition applied to the teeth was calculated as follows: first, the average baseline RED intensity for each reaction zone from step-16 was calculated minus the average RED intensity for the same reaction zone after pressing on the dental disc of step-17 with the residual composition. The calculation was repeated for all reaction zones pressed against the dental disc and the results averaged. This is the average residual peroxide concentration of the composition applied to the teeth.

Additionally or alternatively, the density of the hydrophobic phase used in the semi-solid multi-phase oral composition of the present invention is in the range of about 0.8g/cm3 to about 1.0g/cm3, about 0.85g/cm3 to about 0.95g/cm3, or about 0.9g/cm3, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

Additionally or alternatively, the hydrophobic phase may be a non-toxic oil, such as a non-toxic edible oil. In particular, the hydrophobic phase may comprise non-toxic edible oils, saturated or unsaturated fatty alcohols, aliphatic hydrocarbons, long chain triglycerides, fatty acid esters, and mixtures thereof. Additionally or alternatively, the hydrophobic phase may comprise silicones, polysiloxanes, and mixtures thereof. Preferably, the hydrophobic phase may be selected from mineral oil, petrolatum and mixtures thereof, more preferably petrolatum (e.g. white petrolatum) is used as the hydrophobic phase of the composition of the present invention. Examples of petrolatum include Snow White Pet-C from Calumet Specialty Products (Indianapolis, IN), G-2191 from Sonneborn (Parsippany, NJ), G-2218 from Sonneborn, G-1958 from Sonneborn, G-2180 from Sonneborn, Snow White V28 EP from Sonneborn, Snow White V30 from Sonneborn, G-2494 from Sonneborn, and mixtures thereof. Preferably, the semi-solid multi-phase oral composition comprises petrolatum as the continuous phase, more preferably, petrolatum is the continuous phase of the semi-solid multi-phase oral composition

The aliphatic hydrocarbon may contain from about 10, 12, 14 or 16 to about 16, 18, 20, 22, 24, 26, 28, 30, 36, 40 carbon atoms, such as decane, 2-ethyldecane, tetradecane, isotetradecane, hexadecane, eicosane, and mixtures thereof. The long chain triglycerides may include vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, semi-synthetic triglycerides, and mixtures thereof. These types of fractionated, refined or purified oils may also be used. Examples of long chain triglyceride containing oils include almond oil; babassu oil; borage oil; black currant seed oil; castor oil canola oil; coconut oil; corn oil; cottonseed oil; emu oil; evening primrose oil; linseed oil, grape seed oil; peanut oil falling; mustard oil; olive oil; palm oil; palm kernel oil; peanut oil; rapeseed oil; safflower oil; sesame oil and cod liver oil; soybean oil; sunflower oil; hydrogenated castor oil; hydrogenated coconut oil hydrogenated palm oil; hydrogenated soybean oil; hydrogenated vegetable oil; a mixture of hydrogenated cottonseed oil and hydrogenated castor oil; partially hydrogenated soybean oil; a mixture of partially hydrogenated soybean oil and partially hydrogenated cottonseed oil; triolein; glycerol trilinoleate; glycerol linoleate thrice; omega 3-polyunsaturated fatty acid triglycerides comprising oil; and mixtures thereof. The long chain triglyceride-containing oil may preferably be selected from corn oil, olive oil, palm oil, peanut oil, safflower oil, sesame oil, soybean oil, castor oil, linseed oil, rape oil, rice bran oil, coconut oil, hydrogenated castor oil; partially hydrogenated soybean oil; triolein; glycerol trilinoleate; omega 3-polyunsaturated fatty acid triglycerides comprising oil; and mixtures thereof.

The saturated or unsaturated fatty alcohols may have from about 6 to about 20 carbon atoms, cetyl/stearyl alcohol, lauryl alcohol, and mixtures thereof. For example, Lipowax (cetearyl alcohol and ceteareth-20) supplied by and manufactured by Lipo Chemical.

General information on silicone fluids, gums and resins, and the manufacture of Silicones can be found in Encyclopedia of Polymer Science and Engineering, Vol.15, second edition, p.204-.

The semi-solid multi-phase oral composition as disclosed herein may comprise additional ingredients that may optionally be added and will be described in further detail below.

Preferably, the semi-solid multi-phase oral composition of the present invention may not comprise a dispersing agent. Even when no dispersing agent is used, a multi-phase oral composition can be formed that can be in the form of a particulate semi-solid dispersion. Without being bound by theory, it is believed that even without the use of a dispersant, a low amount of hydrophilic active agent particles, in combination with the rheological properties, flow properties, melting point, drop melting point, freezing point, and/or cone penetration of the hydrophobic phase, and/or the method of preparation of the composition, can help to disperse the hydrophilic active agent particles in the hydrophobic phase and keep them dispersed. Additionally or alternatively, the semi-solid multi-phase oral composition can be substantially free of ingredients such as dispersants (especially dispersants having double or triple bond covalent bonds between adjacent carbon atoms) having the following properties at the temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition can be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer: 1) efficacy, comfort, use experience, concentration of active or bleaching agent at the tooth surface over time, activity or bleaching efficacy, or compatibility between ingredients may be compromised, or 2) may react with other ingredients, degrade other ingredients, cause foam or pressure build-up, reduce the affinity of the semi-solid multi-phase oral composition for the teeth, cause the semi-solid multi-phase oral composition to thicken or harden, or make it difficult or impossible to manually dispense a suitable dose of the semi-solid multi-phase oral composition from a tube, or cause macro-separation of one or more components of the semi-solid multi-phase oral composition. As used herein, "substantially free of dispersant" means that the composition contains less than 0.001% by weight of dispersant. More preferably, the semi-solid whitening multiphase oral composition of the present invention does not contain a dispersant, i.e. does not contain any dispersant. In particular, the semi-solid multi-phase oral composition can be substantially free of ingredients such as water, hydrophilic liquids, glycerin, hydrophilic particles that become tacky when activated by moisture, hydroxyl groups, or combinations thereof, having the following characteristics at temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition can be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer: 1) efficacy, comfort, use experience, concentration of active or bleaching agent at the tooth surface over time, activity or bleaching efficacy, or compatibility between ingredients may be compromised, or 2) foam or pressure may react with or degrade other ingredients, or may cause foam or pressure build-up, reduce the packaged affinity of the semi-solid multi-phase oral composition for teeth, store, cause thickening or hardening of the semi-solid multi-phase oral composition, or make it difficult or impossible to manually dispense a suitable dose of the semi-solid multi-phase oral composition from a tube, or cause macro-separation of one or more components of the semi-solid multi-phase oral composition.

Additionally or alternatively, the semi-solid multi-phase oral composition of the present invention may comprise from 0% to about 0.1%, from about 0.1% to about 4%, from about 0.1% to about 3%, or from about 0.5% to about 1.5%, by weight of the multi-phase oral composition, of water, hydrophilic liquid, glycerin, hydrophilic particles that become tacky when activated by moisture, or a combination thereof. Preferably, the semi-solid multi-phase oral composition of the present invention comprises less than about 0.001%, 0.01%, 0.1%, 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10% or 20% water, hydrophilic liquid, glycerin, hydrophilic particles that become tacky when activated by moisture, or a combination thereof, more preferably, the semi-solid multi-phase oral composition of the present invention comprises 0% water. Thus, the semi-solid multi-phase oral composition of the present invention is preferably non-aqueous, substantially free of added water or anhydrous.

Additionally or alternatively, the semi-solid multi-phase oral composition may be substantially free of ingredients having a strong odor, such as alcohols, solvents, ethyl acetate, heptane, or ingredients having a boiling point below 99 ℃. Without being bound by theory, it is believed that the reduction in surface tension produced by the alcohol may reduce the retention time of the hydrophilic active agent particles on the tooth surface, thereby reducing the efficacy of the oral care active. The presence of acid may be incompatible with the active and/or may produce adverse side effects at the tooth surface, such as hypersensitivity and the like. Thus, the semi-solid multi-phase oral compositions of the present invention are preferably free of acids, free of alcohols, or free of mixtures thereof. In particular, the semi-solid multi-phase oral composition may comprise less than 0.001% acid and/or alcohol by weight of the composition, preferably the semi-solid multi-phase oral composition does not comprise an acid and/or alcohol.

Additionally or alternatively, the hydrophobic phase of the semi-solid multi-phase oral composition can be substantially free of ingredients that can react with other ingredients, such as a bleaching agent.

Additionally or alternatively, the semi-solid multi-phase oral composition may be substantially free of ingredients such as fumed silica, sodium tripolyphosphate, polyorganosiloxanes, condensation products of silicone resins and organosiloxanes, polymers of styrene, polymers of ethylene, polymers of propylene, polyvinylpyrrolidone, glycerin, tin fluoride, or combinations thereof, which have the following properties at the temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition may be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer: 1) efficacy, comfort, use experience, concentration of active or bleaching agent at the tooth surface over time, activity or bleaching efficacy, or compatibility between ingredients may be compromised, or 2) may react with other ingredients, degrade other ingredients, cause foam or pressure build-up, reduce the affinity of the semi-solid multi-phase oral composition for the teeth, cause the semi-solid multi-phase oral composition to thicken or harden, or make it difficult or impossible to manually dispense a suitable dose of the semi-solid multi-phase oral composition from a tube, or cause macro-separation of one or more components of the semi-solid multi-phase oral composition.

In particular, the semi-solid multi-phase oral composition can be easily manually dispensed from the tube after being held at-7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃ or 60 ℃ for 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months or 24 months.

Method test for determining whether a composition is susceptible to being manually dispensed from a tube

1. Foil laminated tubes were selected having the following dimensions:

a. total length from nozzle tip to barrel bottom: about 112mm

b. The inner diameter of the cylinder body is as follows: about 28mm

c. Nozzle length: about 21mm

d. Nozzle bore diameter: half of the length of the nozzle attached to the barrel is about 9.7mm and the other half of the nozzle leading to the nozzle outlet is about 4.2 mm.

2. About 35 grams to about 40 grams of the composition was filled into the step-1 tube through the bottom of the cylinder. The bottom of the barrel was sealed using an ultrasonic sealer.

3. The tube is kept undisturbed in the room or room, wherein the air is kept at said temperature (e.g. -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃ or 60 ℃) for a period of time after which the ease of dispensing will be measured.

4. The tubes were allowed to equilibrate at about 23 ℃ for at least one day.

5. The tube is lifted with the thumb and fingers of one hand. The tube was squeezed firmly between the thumb and the remaining fingers for about 10 seconds while the tube was held in air. The length of the composition bead dispensed from the nozzle of the tube was measured.

6. If at least 1 inch of product is dispensed in step-5, the composition is considered to be readily dispensed manually from the tube after being held at the specified temperature for the specified period of time.

Additionally or alternatively, the semi-solid multi-phase oral composition may be substantially free of fumed silica as it may reduce the stability of the active agent.

Product information documents from the supplier (Dow Corning Corporation) (table No. 52-1052B-01, 2016, 8 months and 9 days) claim that BIO-PSA standard silicone adhesives are provided using heptane or ethyl acetate as solvents, both of which have strong odors, making them unsuitable for use in the oral cavity. The european chemical authority (3 months 2016) states that cyclic siloxane D4 is a persistent, bioaccumulating, and toxic substance, and that cyclic siloxane D5 is a very persistent, very bioaccumulating substance.

Additionally or alternatively, the semi-solid multi-phase oral composition can be substantially free of ingredients such as silicone binders, cyclic silicones, silicone fluids, polydimethylsiloxanes, paraffin oils, mixtures of silicones with hydrocarbons, mixtures of liquid silicones with liquid hydrocarbons, trimethylsiloxysilicate/dimethiconol cross-linked polymer, or combinations thereof, that have the following properties at the temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition can be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer: 1) efficacy, comfort, use experience, concentration of active or bleaching agent at the tooth surface over time, activity or bleaching efficacy, or compatibility between ingredients may be compromised, or 2) may react with other ingredients, degrade other ingredients, cause foam or pressure build-up, reduce the affinity of the semi-solid multi-phase oral composition for the teeth, cause the semi-solid multi-phase oral composition to thicken or harden, or make it difficult or impossible to manually dispense a suitable dose of the semi-solid multi-phase oral composition from a tube, or cause macro-separation of one or more components of the semi-solid multi-phase oral composition.

Additionally or alternatively, the semi-solid multi-phase oral composition may be substantially free of ingredients, such as molecules having double or triple bond covalent bonds between adjacent carbon atoms, that have the following properties at the temperatures (e.g., -7 ℃,4 ℃, 23 ℃,25 ℃,30 ℃, 40 ℃,50 ℃, or 60 ℃) and conditions to which the semi-solid multi-phase oral composition may be exposed during manufacture, filling, transport, or storage (e.g., 1 day, 2 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, or 24 months) prior to use by a consumer: 1) efficacy, comfort, use experience, concentration of active or bleaching agent at the tooth surface over time, activity or bleaching efficacy, or compatibility between ingredients may be compromised, or 2) may react with other ingredients, degrade other ingredients, cause foam or pressure build-up, reduce the affinity of the semi-solid multi-phase oral composition for the teeth, cause the semi-solid multi-phase oral composition to thicken or harden, or make it difficult or impossible to manually dispense a suitable dose of the semi-solid multi-phase oral composition from a tube, or cause macro-separation of one or more components of the semi-solid multi-phase oral composition.

Thickeners, viscosity modifiers or particulate fillers

The semi-solid multi-phase oral compositions herein may comprise a safe and effective amount of a thickening agent, viscosity modifying agent, or particulate filler. Thickeners may also provide acceptable rheological properties of the composition. Viscosity modifiers can also be used to inhibit settling and separation of components or to control settling in a manner that facilitates redispersion, and can control the flow properties of the composition. In addition, thickeners or viscosity modifiers may facilitate use of the present compositions with suitable application devices such as strips, films or trays by increasing retention on the surface of the applicator. Thickeners may also be used as binders, as described herein.

When present, the thickening agent, viscosity modifier or particulate filler may be present at a level of from about 0.01% to about 99%, from about 0.1% to about 50%, from about 1% to about 25%, or from about 1% to about 10%, by weight of the multi-phase oral composition.

Suitable thickeners, viscosity modifiers or particulate fillers for use herein include organically modified clays, silica, synthetic polymers such as cross-linked silicones, cellulose derivatives (e.g., methylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxy-propylmethylcellulose, and the like), carbomer polymers (e.g., cross-linked polyacrylic acid copolymers or homopolymers and copolymers of acrylic acid cross-linked with polyalkenyl polyethers), natural and synthetic gums, karaya gum, guar gum, gelatin, algin, sodium alginate, tragacanth, chitosan, polyethylene oxide, acrylamide polymers, polyacrylic acid, polyvinyl alcohol, polyamines, polyquaternary ammonium compounds, ethylene oxide polymers, polyvinylpyrrolidone, cationic polyacrylamide polymers, waxes (including paraffin and microcrystalline waxes), polyethylene oxide, polyvinyl alcohol, fumed silica, polymethacrylates, olefin copolymers, hydrogenated styrene-diene copolymers, styrene polyesters, rubbers, vinyl chloride, nylon, fluorocarbons, polyurethane prepolymers, polyethylene, polystyrene, alkylated polystyrene, polypropylene, cellulosic resins, acrylic resins, elastomers, poly (n-butyl vinyl ether), poly (styrene co-maleic anhydride), poly (alkyl fumarate co-vinyl acetate), poly (t-butyl styrene), and mixtures thereof.

Examples of polyethylene include A-C1702 or A-C6702 made by Honeywell Corp. (Morristown, NJ), which have penetration values of about 98.5 and about 90.0, respectively, according to ASTM D-1321. Polyethylene performarlene series from Baker Hughes; this includes polyethylene Performalene 400 available from Baker Hughes Inc (Houston, TX). Examples of microcrystalline waxes include the Multiwax series available from Sonneborn (Parsippany, NJ), crompton (witco); these include Multiwax 835, Multiwax 440, Multiwax 180, and mixtures thereof.

Examples of polymethacrylates include, for example, polyacrylate-co-methacrylate, polymethacrylate-co-styrene, or combinations thereof. Examples of elastomers include, for example, hydrogenated styrene-co-butadiene, hydrogenated styrene-co-isoprene, ethylene-propylene polymers, styrene-ethylene-propylene-styrene polymers, or combinations thereof. Examples of rubbers include hydrogenated polyisoprene. Other examples of viscosity index improvers can be found in "Chemistry and Technology of Lubricants", Chapman and Hall (2 nd edition, 1997).

Suitable carbomers include a class of homopolymers of acrylic acid crosslinked with an alkyl ether of pentaerythritol or an alkyl ether of sucrose. Carbomer can be used asSeries are commercially available from b.f. goodrich, such as Carbopol 934, 940, 941, 956, and mixtures thereof. Homopolymers of polyacrylic acid are described, for example, in U.S. Pat. No.2,798,053. Other examples of useful homopolymers include Ultrez 10, ETD 2050, and 974P polymers available from The b.f. goodrich Company (Greenville, SC). These polymers are homopolymers of unsaturated, polymerizable carboxyl monomers such as acrylic acid, methacrylic acid, maleic acid, itaconic acid, maleic anhydride, and the like.

The semi-solid multi-phase oral composition of the invention and/or the hydrophobic phase of the invention may be substantially free of structure building agents, for example amphiphilic copolymers such as polyvinylpyrrolidone-vinyl acetate, polyvinylpyrrolidone-co-polyvinyl butyrate or polyvinylpyrrolidone-co-polyvinyl propionate copolymers, which not only thicken the oral care composition, but also tend or maintain the oral care composition in a homogeneous state. This is because structure building agents such as amphiphilic copolymers 1) have at least one hydrophilic monomer and this can make the semi-solid multi-phase oral composition easier to wash out in saliva or other liquids, or 2) can bring the oral care composition to a homogenous state and this can reduce the concentration of actives or bleaching agents at the tooth surface over time.

Other suitable optional ingredients

Cooling agents, desensitizing agents, and numbing agents can be used as optional ingredients in the compositions of the present invention, for example, at levels of from about 0.001% to about 10%, more specifically from about 0.1% to about 1%, by weight of the composition. Cooling agents, desensitizing agents, and numbing agents can reduce potential adverse sensations such as stinging, burning, and the like. The cooling agent can be any of a wide variety of materials. Among the materials included in the present invention are amides, menthol, ketals, diols, and mixtures thereof. The optional cooling agent in the compositions of the present invention may be a p-menthane carboxamide agent such as N-ethyl-p-menthane-3-carboxamide (referred to as "WS-3"), N,2, 3-trimethyl-2-isopropylbutanamide (referred to as "WS-23"), menthol, 3-1-menthoxypropane-1, 2-diol (referred to as TK-10), menthone glycerol acetal (referred to as MGA), menthyl lactate (referred to as MGA)) And mixtures thereof. As used herein, the terms menthol and menthyl include the dextro-and levorotatory isomers of these compounds as well as the racemic mixtures thereof. Desensitizing agents or analgesics may include, but are not limited to, strontium chloride, potassium nitrate, natural herbs such as gallnut, asarum, cubebin, galangal, scutellaria, zanthoxylum, angelica, and the like. Suitable numbing agents include benzocaine, lidocaine, clove bud oil, and ethanol.

Additionally or alternatively, an anti-inflammatory agent may be present in the semi-solid multi-phase oral composition as disclosed herein. Such agents may include, but are not limited to, non-steroidal anti-inflammatory agents such as acetylsalicylic acid, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, acetaminophen, acetylsalicylic acid, steroids, ketorolac, naproxen, ketoprofen, piroxicam, and meclofenamic acid, COX-2 inhibitors such as valdecoxib, celecoxib, and rofecoxib, and mixtures thereof. Anti-inflammatory agents, if present, are generally present at levels of from about 0.001% to about 5% by weight of the composition.

Additionally or alternatively, nutrients such as minerals may improve teeth and tooth surfaces and thus may be included in the compositions as disclosed herein. Suitable minerals are, for example, calcium, phosphorus, fluorine, zinc, manganese, potassium, and mixtures thereof. These minerals are disclosed, for example, in "Drug Facts and companies" (loose-leaf pharmaceuticals information service), Wolters Kluer Company, st.Pages 10-17.

Additionally or alternatively, the compositions as disclosed herein may optionally comprise a safe and effective amount of a flavoring agent. Suitable flavoring agents include wintergreen oil, peppermint oil, spearmint oil, clove bud oil, menthol, anethole, methyl salicylate, eucalyptol, 1-menthyl acetate, sage, eugenol, parsley oil, hydroxy phenyl butanone, alpha-ionone, origanum, lemon, orange, propenyl guaethol, cinnamon, vanillin, thymol, linalool, cinnamaldehyde glycerol acetal (known as CGA), and mixtures thereof. Flavoring agents, if present, are generally used in amounts of about 0.01% to about 30%, specifically about 1% to about 20%, more specifically about 1.5% to about 15%, by weight of the composition.

Additionally or alternatively, the compositions of the present invention may optionally comprise sweeteners including sucralose, sucrose, glucose, saccharin, dextrose, levulose, lactose, mannitol, sorbitol, fructose, maltose, xylitol, saccharin salts, thaumatin, aspartame, D-tryptophan, dihydrochalcones, acesulfame and cyclamate salts, especially sodium cyclamate and sodium saccharin, and mixtures thereof. If present, the compositions comprise from about 0.1% to about 10%, specifically from about 0.1% to about 1%, by weight of the composition, of these agents.

Additionally or alternatively, dyes, pigments, colorants, and mixtures thereof may optionally be included in the compositions of the present invention to impart a colored appearance to the compositions herein. The advantage of incorporating pigments and/or colorants into the compositions herein is: it enables the user to see if the composition uniformly and completely covers their teeth, as it is easier to see if the coverage is with a colored composition. In addition, the colorant may provide a color similar to a bleached tooth color. The colorants useful in the present invention are stable with bleach and are recognized as safe. Dyes, pigments, and colorants optionally are used herein at levels ranging from about 0.05% to about 20%, specifically from about 0.10% to about 15%, and more specifically from about 0.25% to about 5%, by weight of the composition.

It has been surprisingly found that in the compositions of the present invention, two or more oral care actives that are generally incompatible with each other can be combined in the same composition. For example, the present invention may comprise a combination of hydrophilic bleach particles with additional oral care actives that may further improve the bleaching efficacy of the composition. Examples of such embodiments include the combination of hydrophilic bleach particles with additional oral care actives that can provide a driving force to raise the pH upon contact with water. Specifically, examples include hydrophilic bleach particles comprising peroxide mixed with sodium bicarbonate (baking soda). Notably, US 5,814,303 claims: "peroxide and baking soda react with each other when in contact. Therefore, these components must be kept separately until use. Dispensing packages have been developed that physically isolate the peroxide and baking soda by separating them into distinct compartments. "it has now surprisingly been found that in the present invention, peroxide and baking soda can actually be combined in the same composition, thereby eliminating the need for different compartments. Without being bound by theory: given that dispersing particles of two or more hydrophilic oral care actives that are generally incompatible with each other in a hydrophobic phase can keep the particles substantially separated from each other and have a hydrophobic phase between the particles, such separation can minimize or eliminate incompatibility even on a microscopic scale. Furthermore, it is also assumed that when particles of one of the hydrophilic oral care agents are contacted with moisture, for example when used in the oral cavity, components of the particles may at least partially dissolve or swell and come into direct contact with components of particles of the other oral care agent; however, this may occur primarily when used in the oral cavity, and only minimally or not at all in the composition until then. Thus, the semi-solid multi-phase oral composition of the present invention may comprise two or more oral care actives that are generally incompatible with each other.

Bleaching efficacy

If a bleaching agent is used as the active agent, the bleaching efficacy of the present invention, as measured according to the clinical protocol disclosed herein and calculated as- Δ b, may be at least about 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4,5, 6,7, 8, 9, or 10 or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

Specifically, the bleaching efficacy of the present invention as measured according to the clinical protocol disclosed herein (if applicable) and calculated as- Δ b may be at least about 0.25, preferably at least about 0.5, more preferably at least about 1.0, even more preferably at least about 1.5, even more preferably at least about 2, even more preferably at least about 2.5, even more preferably at least about 3, even more preferably at least about 3.5, and even more preferably at least about 4, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. Generally, a change in yellowness of at least 0.25 as measured according to the clinical protocol disclosed herein and calculated as- Δ b is significant.

The present invention, if applicable, can achieve a surprisingly high ratio of bleaching efficacy to weight percent of bleaching agent present in the overall semi-solid multi-phase oral composition as measured according to the clinical protocol disclosed herein and calculated as-ab. For example, for a composition comprising 3% bleach, a- Δ b of 1.5 would achieve a ratio of bleaching efficacy as measured according to the clinical protocol as disclosed herein and calculated as- Δ b to the weight percentage of bleach present in the overall semi-solid multi-phase oral composition of 0.5.

Additionally or alternatively and if applicable, the ratio of the bleaching efficacy of the present invention to the weight percentage of bleaching agent present in the overall semi-solid multi-phase oral composition as measured according to the clinical protocol disclosed herein and calculated as- Δ b may be at least about 0.25, 0.5, 1, 1.5, 2, 2.5, 5, 10, or 15 or any other range of values that is narrower and falls within such broader range of values as if such narrower range of values were all expressly written herein.

Specifically and if applicable, the ratio of the bleaching efficacy of the present invention to the weight percentage of bleaching agent present in the overall semi-solid multi-phase oral composition as measured and calculated as- Δ b according to the clinical protocol disclosed herein may be at least about 2.5, preferably at least about 5, more preferably at least about 10, even more preferably at least about 15.

Additionally or alternatively and if applicable, the bleaching efficacy of the present invention as measured according to the clinical protocol disclosed herein and calculated as- Δ b may be at least about 10%, at least about 100%, at least about 1000%, or at least about 10,000% greater than the bleaching efficacy of a comparative oral care composition in the form of an aqueous solution or aqueous gel. The comparative oral care compositions comprise the same overall concentration of the same bleaching agent dissolved in an aqueous solution or aqueous gel.

If the hydrophilic active agent particles are bleach particles, the present invention will achieve: 1) a surprisingly high ratio of bleaching efficacy as measured according to the clinical protocol as disclosed herein and calculated as- Δ b to the proportion of participants reporting oral irritation or observed to have oral irritation that may or may be attributable to the tested composition; 2) a surprisingly high ratio of bleaching efficacy as measured according to the clinical protocol as disclosed herein and calculated as-ab treatment to the proportion of participants reporting tooth sensitivity that may or may be attributable to the composition; or 3) a surprisingly high ratio of bleaching efficacy as measured according to the clinical protocol as disclosed herein and calculated as- Δ b to the proportion of participants who reported tooth sensitivity or reported oral irritation or were observed to have oral irritation that may or may be attributable to the composition.

Additionally or alternatively and if applicable, the ratio of bleaching efficacy of the present invention to the proportion of participants reporting tooth sensitivity that may or may be attributable to the present invention, as measured according to the clinical protocol as disclosed herein and calculated as- Δ b, can be at least about 6,7, 8, 9, 10, 15, 20, 25, 50, or 100, or any other range of values that is narrower and falls within such broader range of values, as such narrower range of values are all expressly written herein.

Specifically and if applicable, the ratio of bleaching efficacy of the present invention to the proportion of participants reporting a tooth sensitivity that may or may be attributable to the present invention, as measured according to the clinical protocol disclosed herein and calculated as-ab, may be at least about 6, preferably at least about 7, more preferably at least about 8, even more preferably at least about 9, even more preferably at least about 10, even more preferably at least about 15, even more preferably at least about 20, even more preferably at least about 25, and even more preferably at least about 50, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

Additionally or alternatively and if applicable, the ratio of the bleaching efficacy of the present invention to the reported oral irritation or observed proportion of participants who have oral irritation that may or may be attributable to the present invention, as measured according to the clinical protocol as disclosed herein and calculated as- Δ b, can be at least about 6,7, 8, 9, 10, 15, 20, 25, 50, or 100, or any other range of values that is narrower and falls within such broader range of values, as such narrower range of values are all expressly written herein.

Specifically and if applicable, the ratio of bleaching efficacy of the present invention to the ratio of reported oral irritation or observed participants who have a proportion that can or may be attributable to oral irritation of the present invention, as measured according to the clinical protocol as disclosed herein and calculated as-ab, can be at least about 6, preferably at least about 7, more preferably at least about 8, even more preferably at least about 9, even more preferably at least about 10, even more preferably at least about 15, even more preferably at least about 20, even more preferably at least about 25, and even more preferably at least about 50, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

Additionally or alternatively and if applicable, the ratio of bleaching efficacy of the present invention to reported tooth sensitivity or reported oral irritation or observed proportion of participants who have a proportion of oral irritation that may or may be attributable to the present invention, as measured according to the clinical protocol as disclosed herein and calculated as- Δ b, can be at least about 6,7, 8, 9, 10, 15, 20, 25, 50, or 100, or any other range of values that is narrower and falls within such broader range of values, as such narrower range of values are all expressly written herein.

Specifically and if applicable, the ratio of bleaching efficacy of the present invention to the proportion of participants who report tooth sensitivity or report oral irritation or are observed to have a proportion that can or may be attributable to oral irritation of the present invention, as measured and calculated as-ab according to the clinical protocol as disclosed herein, can be at least about 6, preferably at least about 7, more preferably at least about 8, even more preferably at least about 9, even more preferably at least about 10, even more preferably at least about 15, even more preferably at least about 20, even more preferably at least about 25, and even more preferably at least about 50, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

Clinical protocol

The bleaching efficacy of the semi-solid multi-phase oral compositions was measured using the following clinical protocol. The bleaching efficacy of semi-solid multi-phase oral compositions comprising a bleaching agent as an active agent was measured using the following clinical protocol. For each treatment group, 17 to 25 participants were recruited to complete the clinical study when the test composition had less than about 1% bleach, and 8 to 25 participants were recruited to complete the clinical study when the test composition had at least about 1% bleach. The enrolled participants must have four natural maxillary anterior teeth and all measurable facial sites. The mean baseline L of the participant group must be 71 to 76 and the mean baseline b of the participant group must be 13 to 18. In addition, poor occlusion of the anterior maxillary teeth, severe or atypical intrinsic discoloration, such as caused by tetracycline, fluorosis or incomplete calcification, restoration of the crown or facial surface of the anterior maxillary teeth, self-documented medical history of melanoma, current smoking or tobacco use, light or skin pigment abnormalities, self-documented tooth sensitivity, or prior tooth whitening using professional treatments, over-the-counter kits or research products, were excluded from the study. The participants were provided with a home kit with a Crest Cavity Protection toothpaste and an Oral-B indicator soft manual toothbrush (both from Procter & Gamble, Cincinnati, OH, USA) for use twice daily in a conventional manner.

Participants brushed their teeth with water for 30 seconds using a toothbrush ("Anchor 41tuft whitening toothbrush" from Team Technologies, Inc. Morristown, TN, USA) prior to treatment with the semi-solid multi-phase oral composition. Using polyethylene strips as delivery vehicles, each participant's maxillary anterior teeth were treated once daily with the semi-solid multi-phase oral composition for 60 minutes. The polyethylene strips were 66mm by 15mm in size and 0.0178mm in thickness. From 0.6g to 0.8g of the semi-solid multi-phase oral composition was applied to each polyethylene strip prior to application to the maxillary anterior teeth.

If the semi-solid multi-phase oral composition is used with electromagnetic radiation:

1) after 50 minutes of treatment with the semi-solid multi-phase oral composition on the strip, electromagnetic radiation was applied to the buccal surface of the maxillary anterior teeth for 10 minutes,

2) directing electromagnetic radiation through the strip toward the maxillary anterior teeth and through the semi-solid multi-phase oral composition,

3) the strips need to allow at least about 90% of the electromagnetic radiation of 400nm to 500nm to pass through, and

4) electromagnetic radiation was delivered via four fiber optic cables (model M71L01, available from Thorlabs, Newton, NJ, USA) connected to four high power LEDs with a peak intensity wavelength of 455nm (model M455F1, available from Thorlabs, Newton, NJ, USA) as shown in fig. 6. The four LEDs were each operated at 1000mA using an LED driver and HUB (models DC4104 and DC4100-HUB, available from Thorlabs, Newton, NJ, USA). The exit ends of the four fiber optic cables are mounted behind a transparent interface tube to facilitate reproducible positioning of the electromagnetic radiation against the outer surface of the strip. The exit ends of the four fiber optic cables are about 7mm away from the exit surface of the interface tube, where the electromagnetic radiation passes through the transparent interface tube. The articulator of the interface tube is offset so that the electromagnetic radiation is 7.4mm high towards the transparent window through which the maxillary anterior teeth pass. In addition, the transparent window through which the electromagnetic radiation passes towards the maxillary anterior tooth is 40mm long, measured straight from tip to tip (excluding curves). The exit end of the fiber optic cable is positioned and angled such that the cone of electromagnetic radiation exiting the fiber optic cable is centrally located in a transparent window through which the electromagnetic radiation passes toward the maxillary anterior teeth, as shown in fig. 6. In addition, the exit ends of the four fiber optic cables are spaced such that the cones of electromagnetic radiation are spaced throughout the length of the transparent window through which the electromagnetic radiation passes toward the maxillary anterior teeth, as shown in fig. 6. The intensity of electromagnetic radiation of 400nm to 500nm measured at the central axis of each cone of electromagnetic radiation exiting at the exit face of the transparent window through which the electromagnetic radiation passes toward the maxillary anterior teeth through the transparent window needs to be about 175mW/cm²To about 225mW/cm²As measured by the methods disclosed herein.

Once treatment with the semi-solid multi-phase oral composition was completed for 60 minutes, the strips were removed. The treatment is used once daily for a minimum of 7 days for compositions having less than about 1% bleach and for a minimum of 3 days for compositions having at least about 1% bleach.

The change in tooth color due to treatment with the semi-solid multi-phase oral composition was measured using the procedure described below, for compositions having less than about 1% bleach on the day after the 7 th treatment and for compositions having at least about 1% bleach on the day after the 3 rd treatment.

Tooth color was measured using a digital camera (camera model Canon EOS 70D with NIKON 55mm micro-NIKKOR lens with adapter) with a lens equipped with a polarizing filter. The lamp system was provided by a Dedo lamp (model DLH2) equipped with a 150 watt, 24V bulb model (Xenophot model HL X64640), positioned about 30cm apart (measured from the center of the outer circular surface of one to the other of the glass lenses through which the light exited), and aimed at a 45 degree angle so that the light paths intersect at the vertical plane of the chin rest at about 36cm in front of the focal plane of the camera. Each light had a polarizing filter (Lee 201 filter) and a color reducing filter (Rosco 7 mil Thermashield filter available from Rosco, Stamford, CT, USA).

At the intersection of the optical paths, a fixed chin rest is mounted for repositioning in the light field. The camera is placed between the two lamps so that its focal plane is about 36cm from the vertical plane of the chin rest. Before starting to measure tooth color, the color standard is imaged to establish a calibration set point. Munsell N8 gray scale was first quasi-imaged. The white balance of the camera was adjusted so that the RGB value of the gray color was 200. The color standard is imaged to obtain the standard RGB values of the color chip. Color standards and gray scale standards are listed in fibers (obtained from Brand of Munsell Color, X-rite, Grand Rapids, MI, USA). Each color standard is labeled with Munsell nomenclature. To create a grid of color standards, they may be arranged as follows. This allows multiple color standards to be included in a single image that captures a grid of color standards.

Color standard grid 1

7.5R 6 8	2.5R 6 10	10YR 6.5 3	Polarization inspection	5R 7 8	N 3.5 0
						7.5RP 6 6	10R 5 8	5YR 7 3	2.5Y 8.5 2	2.2YR 6.47 4.1	7.5YR 7 4
5YR 8 2	N 8 0	10R 7 4	N 8 0	5YR 7.5 2.5	2.5Y 8 4
						5YR 7 3.5	5YR 7 2.5	5YR 5 2	5YR 7.5 2	N 6.5 0	N 9.5 0

Color standard grid 2

5YR 7.5 3.5	2.5Y 6 4	10YR 7.5 3.5	2.5R 7 8	7.5R 7 8	10YR 7.5 2
						10YR 7.5 2.5	N 5 0	2.5R 6 8	10YR 7 2	5R 7 4	10YR 7 2.5
N 6.5 0	7.5RP 6 8	7.5R 8 4	5Y 8 1	7.5YR 8 2	2.2YR 6.47 4.1
						N 5 0	2.5Y 8 4	10YR 7 3	N 9.5 0	10RP 7 4	2.5Y 7 2

Color standard grid 3

5R 6 10	N 8.5 0	10YR 6.5 3.5	10RP 6 10	N 8 0	7.5YR 7 3
						2.5Y 3.5 0	10YR 7 3.5	5Y 8.5 1	5YR 8 2.5	5YR 7.5 3	5R 5 6
10YR 7.5 3	5YR 6.5 3.5	2.5YR 5 4	2.5Y 8 2	10YR 8 2	2.5Y 7 2
						2.5R 6 6	5R 7 6	10YR 8 2.5	10R 5 6	N 6.5 0	7.5YR 8 3

For baseline tooth color, participants brushed their teeth with water using a toothbrush ("the Anchor 41tuft white toothbrush" from Team Technologies, Inc. Morristown, TN, USA) to remove debris from the teeth. Each participant then pulled the cheek back using a cheek retractor (from Scientific Camera Company, Sumner, WA, USA; treated with a frosted matte surface at A & B deburrring Company, Cincinnati, OH, USA) and the facial surface of their teeth illuminated. Each participant was instructed to bite their teeth together so that the incisal edges of the maxillary incisors contacted the incisal edges of the mandibular incisors. The participant was then positioned on the chin rest at the intersection of the optical path in the center of the camera field of view and an image of the tooth was captured. After all participants were imaged, the images were processed using image analysis software (Optimas manufactured by Media Cybernetics of Silver Spring, MD). The middle four incisors are separated and the average RGB values of the teeth are extracted.

After the participant used the whitening product, but before capturing the dental images of the participant, the system was set to the baseline configuration and calibrated as previously discussed. After calibration, each participant was imaged a second time using the same procedure as before, ensuring that the participant was in the same physical position, including the orientation of the teeth, as the pre-processed image. The images were processed using image analysis software to obtain the average RGB values for the middle four maxillary incisors. The RGB values for all images were then mapped to the CIE L a b color space using the RGB values and the L a b values of the color chips on the color standard. The L a b values of the color chips on the color standard were measured using Photo Research SpectraScan PR650 from Photo Research inc. The PR650 is positioned at the same distance from the color standard as the camera. After calibration, L a b of each chip was measured individually according to the manufacturer's instructions. The RGB values are then converted to L a b values using a regression equation, such as:

L*＝25.16+12.02*(R/100)+11.75*(G/100)–2.75*(B/100)+1.95*(G/100)³

a*＝-2.65+59.22*(R/100)-50.52*(G/100)+0.20*(B/100)–29.87*(R/100)²+20.73*(G/100)²+8.14*(R/100)³-9.17(G/100)³+3.64*[(B/100)²]*[R/100]

b*＝-0.70+37.04*(R/100)+12.65*(G/100)-53.81*(B/100)-18.14*(R/100)²+23.16*(G/100)*(B/100)+4.70*(R/100)³–6.45*(B/100)³

r of L, a and b²Should be used for>0.95. Each study should have its own formula.

These formulas are generally effective conversions (60) in the region of tooth color<L*<95，0<a*<14，6<b*<25). Data from the image set of each participant was then used to calculate product whitening performance from the changes in L, a, and b — a standard method for assessing whitening benefit. When evaluating compositions with less than about 1% bleach: the change in L is defined as Δ L ═ L-_{Day after 7 treatments}-L*_{Base line}Wherein a positive change indicates an improvement in brightness; the change in a (red-green balance) is defined as Δ a ═ a ·_{Day after 7 treatments}-a*_{Base line}Wherein a negative change indicates a less red tooth; the change in b (yellow-blue balance) is defined as Δ b ═ b-_{Day after 7 treatments}-b*_{Base line}Wherein a negative change indicates that the tooth has become less yellow. When evaluating compositions having at least about 1% bleach: the change in L is defined as Δ L ═ L-_{After 3 times of treatment}-L*_{Base line}Wherein a positive change indicates an improvement in brightness; the change in a (red-green balance) is defined as Δ a ═ a-_{After 3 times of treatment}-a*_{Base line}Wherein a negative change indicates a less red tooth; the change in b (yellow-blue balance) is defined as Δ b ═ b-_{After 3 times of treatment}-b*_{Base line}Wherein a negative change indicates that the tooth has become less yellow. - Δ b is used as the primary measure of bleaching efficacy. The overall color change is given by the formula Δ E ═ Δ L²+Δa*²+Δb*²)^1/2To calculate.

After using the whitening product, the color change of the CIE Lab color space can be calculated for each participant based on a given formula.

To validate the above clinical protocol, the bleaching efficacy (calculated as- Δ b) of the validation compositions specified below (delivered on the strip and used with electromagnetic radiation as disclosed herein) needs to be measured and confirmed as >0.5 on the day after the 7 th treatment.

Validated compositions for clinical protocols	(wt%)
		35% aqueous solution H2O2 1	0.2857
Vaseline2	99.7143
		Total of	100.00
Total oral composition H2O2％	0.099995
		Ratio of	350.02

H present in the aqueous phase₂O₂In a weight percent concentration with respect to H present in the total composition₂O₂Is heavyRatio of the quantity percent concentration

¹Super cosmetic grade from Solvay, Houston, Texas

²Grade G-2191 available from Sonneborn, LLC., Parsippany, NJ

Procedure for preparing validated compositions for clinical protocols

By weighing hydrogen peroxide (H)₂O₂) Is placed in a Speedmixer container ("Max 300Long Cup Translucent", product number 501218 t, available from Flacktek inc., Landrum, SC) and stirred in the Speedmixer at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes to prepare a 500 gram batch of the authentication composition. The wall of the vessel was then scraped with a plastic spatula and the contents were again stirred at 800RPM for 5 seconds, 1200RPM for 5 seconds and 1950RPM for 2 minutes. The walls of the vessel were then scraped with a plastic spatula and the contents were stirred a third time at 800RPM for 5 seconds, 1200RPM for 5 seconds and 1950RPM for 2 minutes.

Optional application System

In addition, the present invention may also relate to a delivery system for delivering the present composition to the surface of the teeth. For example, the compositions of the present invention can deliver health or cosmetic benefits, such as delivering whitening benefits to the oral cavity, by direct application to the teeth without the use of a delivery vehicle system. In addition, the present invention may include a delivery system comprising the composition of the present invention in combination with a delivery vehicle. For example, the delivery system can include a first layer of carrier material and a second layer comprising a semi-solid multi-phase oral composition as described herein, whereby the active agent is releasably located in the composition of the present invention. Suitable first layers may comprise a delivery vehicle comprising strips of material, trays, sponge material, and mixtures thereof. In particular, the delivery vehicle may be a strip of material, such as a permanently deformable strip. Suitable strips of material or permanently deformable strips are disclosed, for example, in U.S. patents; 6,136,297, 6,096,328, 5,894,017, 5,891,453 and 5,879,691; and in U.S. Pat. nos. 5,989,569 and 6,045,811; and patent application US 2014/0178443 a 1.

The delivery vehicle may be attached to the teeth via an attachment device that is part of the delivery vehicle, e.g., the delivery vehicle may be of sufficient size such that once applied, the delivery vehicle and oral soft tissue overlap, rendering more of the tooth surface available for treatment. The delivery vehicle may also be attached to the oral cavity by physical interference or mechanical interlocking between the delivery vehicle and oral surfaces, including teeth.

The delivery vehicle may be transparent or translucent to electromagnetic radiation having a wavelength of about 200nm to about 1700 nm. For example, the delivery vehicle allows about 10%, 20%, or 30% to about 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the electromagnetic radiation of about 400nm to about 500nm to pass through to reach the tooth surface.

When the delivery vehicle is a strip of material, the second layer composition may be coated onto the strip, or applied by the user onto the teeth, and then the strip is placed over the coated teeth. The amount of composition applied to the strip or teeth may depend on the size and capacity of the strip, the concentration of the active, and the desired benefit; for example, compositions of about 0.0001 grams, 0.001 grams, or 0.01 grams to about 0.01 grams, 0.1 grams, 1 gram, or 5 grams, or any other range of values that is narrower and falls within such broader range of values may be used, as if such narrower range of values were all expressly written herein, specifically, about 0.001g to about 0.5g, or about 0.1g to about 0.4g of the semi-solid multi-phase oral composition may be used. In addition, from about 0.0001, 0.001, or 0.01 grams to about 0.01, 0.1, 0.5, or 1 gram of the composition per square centimeter of material (g/cm) can be used²) Or any other numerical range that is narrower and falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein; in preferred embodiments, less than about 0.2g/cm²About 0.0001g/cm²To about 0.1g/cm²Or about 0.01g/cm²To about 0.04g/cm². Additionally or alternatively, about 1 microgram to about 5000 micrograms of active or bleaching agent per square centimeter of material (microgram/cm 2), preferablyPreferably from about 10 micrograms/cm 2 to about 500 micrograms/cm 2 and more preferably from about 50 micrograms/cm 2 to about 100 micrograms/cm 2 of active or bleaching agent per square centimeter of material.

Referring now to the drawings, and more particularly to fig. 1, there is shown an embodiment of a suitable delivery system 10 representing a delivery system for delivering a bleaching active provided by a semi-solid multi-phase oral composition as disclosed herein to the teeth and oral cavity. The delivery system 10 includes a material in the form of a strip 12 of material that is substantially flat and may have rounded corners. On the strip 12, a second layer 14 comprising a semi-solid multi-phase oral composition of the present invention is releasably applied. The second layer 14 may be uniform and may be uniformly applied to the strip 12, as shown in the cross-sectional view of fig. 2. Further, the second layer 14 comprising the composition of the present invention may be a coating along the longitudinal axis of only a portion of the strip of material 12, or may be applied in stripes, dots, and/or other patterns. Alternatively, however, the second layer 14 can be a laminate or separate layers of components, an amorphous mixture of components, separate strips or dots or other patterns of different components, or a combination of these structures that includes a coating of the second layer 14 along the longitudinal axis of a portion of the strip of material 12.

Additionally or alternatively, the second layer 14 may comprise an active substance, or be an active substance itself, such as a composition, compound or mixture capable of affecting or effecting a desired change in the appearance or structure of a surface in contact therewith. As previously discussed, exemplary actives include: hydrogen peroxide, urea peroxide, sodium fluoride, sodium monofluorophosphate, pyrophosphate, chlorhexidine, polyphosphate, triclosan, and enzymes. Examples of changes in appearance and structure include, but are not limited to, whitening, stain bleaching, stain removal, remineralization to form fluorapatite, plaque removal, and tartar removal.

In addition, the second layer 14 composition may include an adhesive means for stably attaching the delivery system 10 to a tooth surface. The compositions as disclosed herein may provide the desired tack and adhesion by themselves, for example by selecting a hydrophobic phase that provides adhesive properties by adding adhesive material to the compositions of the invention, or both. If added, the binder may provide additional properties, such as thickening/rheology modifying properties.

Fig. 3 and 4 illustrate the delivery system 10 of the present invention applied to the dental surface of a plurality of adjacent teeth. A plurality of adjacent teeth 22 are embedded in adjacent soft tissue 20. Adjacent soft tissue 20 is defined herein as the soft tissue surface surrounding a tooth structure, which includes: gingival papillae, marginal gingiva, gingival sulcus, interdental gingiva, and from the gingival structures on the lingual and buccal surfaces up to the muco-gingival junction on the palate (including the junction).

In fig. 3 and 4, the delivery system 10 represents the strip 12 and a second layer 14 comprising the composition of the present invention, wherein the second layer 14 is located on the side of the strip of material 12 facing the teeth 22. The composition of the second layer 14 may be pre-applied to the strip of material 12 or may be applied to the strip of material 12 by the user prior to application to the teeth. Alternatively, the composition of the second layer 14 may be applied directly to the teeth 22 by the user and then covered by the strip 12. In any event, the strip of material 12 can have a thickness and bending stiffness such that it can conform to the surface contours of the teeth 22 and adjacent soft tissue 20. Thus, the strip of material 12 may have sufficient flexibility to be formed into the contours of the oral surface, which is the plurality of adjacent teeth 22. The strip 12 can also readily conform to tooth surfaces and tooth spaces without permanent deformation when the delivery system 10 is applied. The delivery system 10 may be applied without significant pressure.

The first layer 12 of the delivery system 10 may be comprised of a strip of material. Such first layer materials are described in more detail in U.S. patents; 6,136,297, 6,096,328, 5,894,017, 5,891,453 and 5,879,691; and in U.S. Pat. nos. 5,989,569 and 6,045,811; and patent application US 2014/0178443 a 1. The strip 12 acts as a protective barrier for the active agent in the second layer 14. It prevents leaching or erosion of the second layer 14, for example by the wearer's tongue, lips and saliva. This allows the hydrophilic active agent particles in the second layer 14 to act on the tooth surfaces 22 of the oral cavity for a desired period of time, such as a few minutes to a few hours.

The following description of a strip of material is applicable to a delivery system 10 having a strip layer 12 as shown in fig. 1-4 or any form of strip. The material strips may comprise polymers, natural and synthetic spun materials, non-spun materials, foils, paper, rubber, and combinations thereof. The strip of material may be a single layer of material or a laminate of more than one layer of material. Regardless of the number of layers, the strip of material may be substantially water-insoluble. The material strip may also be water-impermeable. Suitable strip materials may be any type of polymer or combination of polymers that meets the desired flexural rigidity coefficient and is compatible with the oral care substance. Suitable polymers include, but are not limited to, polyethylene, ethyl vinyl acetate, polyesters, ethyl vinyl alcohol, and combinations thereof. Examples of polyesters includeAnd fluoroplastics such asAre all manufactured by dupont. In particular, the material used as the material strip is polyethylene. The strip of material may be less than about 1mm (millimeters) thick, less than about 0.05mm thick, or from about 0.001 to about 0.03mm thick. The strip of polyethylene material may be less than about 0.1mm thick, or from about 0.005 to about 0.02mm thick.

Additionally or alternatively, the present invention may comprise a dissolvable film that can adhere to the oral cavity, releasing the active, the dissolvable film comprising a water soluble polymer, one or more polyols, and one or more actives. In addition to one or more active substances, the soluble film may contain certain combinations of plasticizers or surfactants, colorants, sweeteners, flavors, flavor enhancers, or other excipients commonly used to modify the taste of formulations intended for application to the oral cavity. The resulting dissolvable film is characterized by instant wettability, which allows the dissolvable film to soften quickly after application to mucosal tissue, preventing the user from experiencing any long-term adverse sensations in the oral cavity, and having a tensile strength suitable for normal coating, cutting, slitting and packaging operations.

The dissolvable film may comprise a water soluble polymer or combination of water soluble polymers, one or more plasticizers or surfactants, one or more polyols, and an active.

Polymers for use in the soluble film include hydrophilic and/or water-dispersible polymers. Examples of polymers that can be used include polymers that are water-soluble cellulose derivatives, such as hydroxypropyl methylcellulose, hydroxyethyl cellulose, or hydroxypropyl cellulose, either alone or in mixtures thereof. Other optional polymers include polyvinylpyrrolidone, carboxymethylcellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, natural gums such as xanthan gum, tragacanth gum, guar gum, acacia gum, gum arabic, water-dispersible polyacrylates such as polyacrylic acid, methyl methacrylate copolymers, carboxyvinyl copolymers. The concentration of water-soluble polymer in the finished film may vary between 20% and 75% (w/w), or between 50% and 75% (w/w).

The surfactant useful in the soluble film may be one or more nonionic surfactants. When a combination of surfactants is used, the first component may be a polyoxyethylene sorbitan fatty acid ester or an α -hydro- ω -hydroxypoly (oxyethylene) poly (oxypropylene) poly (oxyethylene) block copolymer, while the second component may be a polyoxyethylene alkyl ether or a polyoxyethylene castor oil derivative. The HLB value of the polyoxyethylene sorbitan fatty acid ester, if present, should be between 10 and 20, and thus a range of 13 to 17 may also be used. The α -hydro- ω -hydroxypoly (oxyethylene) poly (oxypropylene) poly (oxyethylene) block copolymer may contain at least about 35 oxypropylene units, and preferably not less than about 50 oxypropylene units.

The polyoxyethylene alkyl ether may have an HLB value between 10 and 20, and preferably, an HLB value of not less than 15 may be used. The polyoxyethylene castor oil derivative may have an HLB value of 14 to 16.

To achieve the desired instant wettability, the ratio between the first and second components of the binary surfactant mixture may be maintained within 1:10 and 1:1, or between 1:5 and 1: 3.

The total concentration of surfactant in the soluble film depends on the identity of the other ingredients, but may typically be between 0.1% and 5% (weight/weight).

Polyols can be used to achieve a desired level of softness of the soluble film. Examples of polyols include glycerol, polyethylene glycol, propylene glycol, monoglycerides with fatty acids, or other pharmaceutically used polyols. The concentration of the polyol in the dry film is generally in the range between 0.1% and 5% (weight/weight).

The shape of the strip of material can be any shape or size that covers the desired oral surface. For example, the strip of material may have rounded corners to avoid irritation of soft tissue in the oral cavity. As used herein, "rounded corners" refers to angles or angles that are generally free of any sharp or pointed points, such as 135 ° or less. The length of the strip of material may be from about 2cm (centimeters) to about 12cm or from about 4cm to about 9 cm. The width of the strip of material may also depend on the oral surface area to be covered. The width of the strip of material may be from about 0.5cm to about 4cm, or from about 1cm to about 2 cm. The strip of material may be worn as a patch on one or more teeth to treat a localized condition.

The strip of material may comprise dimples. When the semi-solid multi-phase oral composition is applied to the strip of material, the bleaching agent and/or oral care active fills the depressions to provide a reservoir of additional bleaching agent and/or oral care active. In addition, the dimples also help to provide texture to the delivery system. The strip of material may have a series of dimples. The dimples are typically about 0.4mm wide and about 0.1mm deep. When dimples are included in the strip of material and the semi-solid multi-phase oral composition herein is applied thereto at different thicknesses, specifically the overall thickness of the delivery system is less than about 1mm, more specifically the overall thickness is less than about 0.5 mm.

Flexural stiffness is a property of a material that is a complex function of the thickness, width, and elastic modulus of the material. The test described below is a method of measuring the stiffness of films, such as polyolefin films and polyolefin sheets. The method measures the bending resistance of a sample by using a strain gauge fixed to the end of a horizontal beam. The other end of the beam is pressed across the sample strip forcing a portion of the strip into a vertical groove on a horizontal platform (for resting the sample). And connecting the microammeter calibrated by the deflection force to the strain gauge by using a metal wire. The stiffness coefficient of the sample can be read directly from the microammeter and is expressed as grams per centimeter of sample strip width. Strips of material suitable for use as delivery vehicles for compositions as disclosed herein may exhibit a flexural stiffness of less than about 5g/cm as measured on a hand tester (model 211-300, available from Thawing-Albert Instrument Company, Philadelphia, Pa.) according to test method ASTM D2923-95. The strip can have a flexural stiffness of less than about 3g/cm, less than about 2g/cm, or a flexural stiffness of from about 0.1g/cm to about 1 g/cm. In general, the flexural stiffness of the strip of material may be substantially constant and does not change during normal use. For example, the strip of material need not be combined with water to achieve a low flexural stiffness in the above range. This relatively low hardness allows the strip of material to cover the contours of the oral surface with slight force. This means that the material strip can be maintained in conformity with the contours of the wearer's oral surface, since the residual stresses within the material strip are small, which stresses cause the material strip to return to its pre-use shape, for example a substantially flat shape. For example, the flexibility of the strip of material allows it to be in contact with soft tissue for extended periods of time without irritation of the soft tissue; so that the strip of material does not require pressure to be held against the oral surface.

As used herein, delivery systems may include adhesive means such that they are capable of adhering to oral surfaces, particularly teeth. The adhesive means may be provided by the inventive composition herein, or the adhesive means may be provided separately from the composition herein (e.g., the adhesive means is a separate phase from the composition herein, wherein the composition may also have an adhesive means). For example, the strip of material is held in place on the oral surface by the adhesion provided by the composition of the present invention. The viscosity and general stickiness of the semi-solid multi-phase oral composition to dry surfaces can result in the strip adhering to the oral surfaces without significant slippage due to the frictional forces generated by the strips of lip, tooth, tongue and other oral surface rubbing material while talking, drinking, etc. However, such adhesion to the oral surface may be low enough to allow the wearer to easily remove the strip of material by simply peeling it off using his fingers. The delivery system can be easily removed from the oral surface without the use of tools, chemical solvents or agents, or excessive friction.

In addition, the strip of material may be held in place on the oral surface by the adhesive means and adhesion provided by the delivery vehicle itself. For example, the strip of material may extend, adhere and adhere to the soft oral tissue. In addition, the adhesive may be applied to the portion of the strip of material that will attach the delivery system to the soft tissue of the oral cavity. The delivery vehicle may also be attached to the oral cavity by physical interference or mechanical interlocking between the delivery vehicle and oral surfaces, including teeth. Furthermore, the strip of material may be held in place by an adhesive means separate from the composition of the invention herein, as disclosed in WO 03/015656.

Suitable adhesive means are known to the skilled person. When the adhesive means (if present) is provided by an adhesive, the adhesive can be any adhesive useful for adhering a material to a tooth surface or a surface of an oral surface. Suitable adhesives include, but are not limited to, skin, gum and mucosal adhesives, and should be able to withstand moisture, chemicals and enzymes in the oral environment for a sufficient period of time to allow the oral care actives and/or bleaching agents to act, but then be dissolvable and/or biodegradable. For example, suitable adhesives may include water soluble polymers, hydrophobic and/or non-water soluble polymers, pressure and moisture sensitive adhesives, such as dry adhesives that become tacky upon contact with the oral environment, e.g., the effects of moisture, chemicals, or enzymes in the oral cavity. Suitable adhesives include natural gums, synthetic resins, natural or synthetic rubbers, those gums and polymers listed above as "thickeners" and various other adhesive substances of the type used in known tapes, which are known from US2,835,628.

The delivery vehicle, such as a tape, as shown, for example, in fig. 1-4, can be formed by several film-making processes known in the art. For example, polyethylene tapes are made by blowing or casting. Other methods are possible including extrusion or methods that do not affect the flexural rigidity of the strip. Further, the inventive composition forming the second layer to the tape strip may be bonded to the tape strip during processing of the tape strip and/or the inventive composition may be a laminate layer on the tape strip. The second layer of the strip attached to such a delivery system as disclosed above comprises a safe and effective amount of the composition described herein.

In addition, the delivery system may include an optional release liner. Such release liners may be formed from any material that exhibits an affinity for the second layer composition that is less than the affinity exhibited by the second layer composition for itself and for the strip of first layer material. Release liners comprise a rigid sheet-like substance, such as polyethylene, paper, polyester, or other material, which is coated with a non-stick type material. The release liner may be cut to substantially the same size and shape as the strip of material, or the release liner may be cut larger than the strip of material, thereby facilitating the user in separating the liner material from the strip of material. The release liner is constructed of a frangible material such that it will break apart when the strip is bent, or it may be constructed of multiple pieces of material or a scored piece of material. Alternatively, the release liner may be in the form of two sheets folded in half, such as the typical adhesive bandage design. A description of materials suitable for use as strippers can be found in Kirk-Othmer, Encyclopedia of Chemical Technology, fourth edition, volume 21, pages 207-218.

For example, the delivery vehicle may be a permanently deformable strip of material having a yield point and a thickness such that the strip of material substantially conforms to the shape of the teeth via permanent deformation at a pressure of less than about 250,000 pascals, as it has been found that the wearer will press the strip against each tooth using one fingertip having a surface area of about one square centimeter. They generally apply a force at each tooth for one second or less with a typical applied pressure in the range of about 100,000 pascals to about 250,000 pascals.

In particular, the strip of material has viscoelastic properties that enable it to creep and bend so as to conform around several teeth and arcuate portions of the wearer's mouth. It is important that the necessary permanent deformation occur with a minimum normal force applied by the wearer.

The semi-solid multi-phase oral composition may also be applied to the tooth surface and may be covered with the deformable strip either before or after the deformable strip is formed. Additionally or alternatively, the semi-solid multi-phase oral composition can be applied to the deformable strip as a pre-coat and can be applied to the tooth surface along with the strip before or after the deformable strip is formed, wherein the strip is applied such that when the delivery system is placed on the tooth surface, the semi-solid multi-phase oral composition contacts the tooth surface, thereby providing the active on the tooth surface. Additionally or alternatively, the strip of deformable material may be applied to the teeth with a force sufficient to shape the delivery vehicle such that it at least partially conforms to the shape of the teeth, the shaped strip of material may then be removed from the tooth surface, the oral care composition may be applied to the shaped strip of material, and the shaped strip of material may be reapplied to the tooth surface such that it at least partially applies to the shape of the teeth and contacts the oral care composition against the tooth surface. If the deformable strip is applied to a tooth surface along with the semi-solid multi-phase oral composition, the semi-solid multi-phase oral composition may further comprise a binder to hold the delivery system in place for a sufficient time to allow the active of the semi-solid multi-phase oral composition to act on the surface. If used with deformable strips, the semi-solid multi-phase oral composition can have an extrusion resistance sufficient to withstand the normal force applied to shape the deformable material strips such that the substance is not substantially extruded from between the deformable material strips and the surface during manual shaping of the deformable material strips. By "substantially extruded from … …," it is meant that at least 50% or more of the semi-solid multi-phase oral composition is extruded between the strip of deformable material and the teeth and adjacent soft tissue surfaces.

The strip of deformable material may be made of a permanently deformable material, such as wax, putty, tin or foil, in a single layer or a combination of layers or materials, such as a laminate. In particular, the deformable strip may be a wax, such as a #165 flake wax, formulated and manufactured by Freeman Mfg. & Supply co. This particular wax readily conforms to the shape of the teeth under a pressure of about 133,000 pascals, which is the pressure that occurs when a wearer exerts a normal force of about 3 pounds (1.36kg) over an area of about one square centimeter. The strip of deformable material may have a nominal film thickness of about 0.8mm, wherein the deformable strip may be substantially flat and rectangular in shape with rounded corners. The strip of deformable material may have a length sufficient to cover a plurality of adjacent teeth while conforming to the curvature of the wearer's mouth and the spaces between adjacent teeth. If the strip of deformable material comprises a semi-solid multi-phase oral composition applied thereto, the semi-solid multi-phase oral composition may have an overall thickness of less than about 1.5 mm. The deformable strip as disclosed herein may also be used as the material of the strip of material 12 shown in fig. 1-4. Thus, the general features of the material strip as described above, for example with respect to fig. 1 to 4, may also be applied to the deformable material strip. Further, the release liner and/or dimples may also be combined with strips of deformable material.

The compositions of the present invention may be used in combination with a delivery vehicle that includes a tray and/or a foam material. Dental trays are well known in the whitening art and an exemplary dental tray 30 is shown in fig. 5. The general process for making the tray 30 is known in the art. Dentists have traditionally used three dental appliances to bleach teeth.

The first category is rigid appliances that fit precisely against the dental arch of the oral user. For example, an alginate impression is made which records all tooth surfaces and gingival margin areas, whereby the impression can be quickly cast into a mold. If a reservoir is required, it is prepared by making a layer of rigid material over the mold on the particular tooth surface to be treated. The tray may then be vacuum formed from the modified mold using conventional techniques. Once formed, the tray is preferably trimmed to remove the gingival margin on the buccal and lingual surfaces. Sufficient tray material should be left to ensure that all teeth are covered to the gingival margin at about 1/4 to about 1 ≧ H on the periphery of the finished and angled tray₃Within mm. The denture is cut into fan shape along the interteeth process to make the teeth completeThe finished trays do not cover them. All tray edges are preferably smooth in shape so that the lips and tongue do not feel the edge prominence. The resulting tray provides a perfect fit to the user's teeth, optionally with a reservoir or space for rigid material to be placed over the mold. The tray may be constructed of a soft, transparent vinyl material that is preformed to a thickness of about 0.1cm to about 0.15 cm. The soft material makes the patient wear more comfortable. Higher durometer materials (or thicker plastic materials) may also be used to make the tray.

The second category of rigid custom dental devices is an "extra-large" rigid custom dental device. Manufacturing a rigid custom dental device entails making a mold of an impression of the user's dental arch and heating and vacuum forming a thermoplastic sheet to conform to the mold of the user's dental arch. Thermoplastic films are sold in the form of rigid or semi-rigid sheets and are provided in a variety of sizes and thicknesses. The dental laboratory manufacturing technique for extra-rigid dental devices involves enlarging the tooth surface on a mold with, for example, die spacer material or cured acrylic (cured/micro-cured). The thermoplastic sheet is then heated and subsequently vacuum formed around the enlarged mold of the dental arch. The net effect of this approach results in an "oversized" rigid custom dental device.

A third class of rigid custom dental devices that have been used only rarely are rigid two-layer custom dental devices fabricated from layered materials, ranging from soft porous foams to rigid non-porous films. The nonporous, rigid thermoplastic outer shell of these dual layer tooth compression devices encases and supports the inner layer of soft porous foam.

A fourth type of tray replaces the rigid custom dental devices with disposable U-shaped soft foam trays that can be individually packaged and saturated with a pre-measured amount of the composition of the present invention. The flexible foam material is typically an open-cell plastic material. Such devices are available under the trade name Vitalwhite from Cadco Dental Products, located in Oxnard, Calif^TMAre commercially available. These soft foam dental trays may include a backing material (e.g., a closed cell plastic backing material) to reduce the outflow of the active agent from the device into the oral cavity, reducing the ingestion by the user and/or irritation of the oral tissue. Alternatively, the soft foam tray is non-porous flexibleThe polymer envelope, or open cell foam, is attached to the front inner wall of the dental device and/or the open cell foam is attached to the rear inner wall of the dental device. Those of ordinary skill in the art will readily recognize and appreciate that the present compositions must be sufficiently viscous to not readily flow out of between the open cell structures of the foam, and sufficiently thin to flow slowly through the open cell foam for extended periods of time. In other words, the open cell foam material has an internal structural spacing that is sized relative to the viscosity of the composition and enables the composition to flow through.

An example of a closed cell material is a closed cell polyolefin foam sold under the trade name Volora by Sekisui America Corporation of Lawrence, mass, division Voltek, having a thickness of 1/32 "to 1/8". Closed cell materials also include flexible polymeric materials. An example of an open cell material is open cell polyethylene Foam sold under the trade name Opcell by Packaging Industries Group, Inc., of Hyannis, Mass., and having a thickness of 1/16 "to 3/8". Other open cell foams useful in the present invention include hydrophilic open cell foams such as hydrogel polymers (e.g., Medicell @)^TMFoams, available from Hydromer, inc. Open-cell foams are also hydrophilic open-cell foams that are absorbed with agents to impart high absorbency to fluids, such as polyurethane or polyvinylpyrrolidone that are chemically absorbed with various agents.

Preparation of the semi-solid multiphase oral composition of the present invention

Principally, the preparation of particulate semi-solid dispersions is well known in the art, and any suitable manufacturing method may be used to prepare the semi-solid multi-phase oral composition, which may be in the form of a particulate semi-solid dispersion. Generally, these components are classified into those that are hydrophilic and those that are hydrophobic. The two phases are then mixed, if necessary under heating, and the product is stirred and then optionally cooled. After combining the phases, the semi-solid multi-phase oral composition of the present invention, which may be in the form of a particulate semi-solid dispersion, may be agitated or sheared by various methods including shaking, batch shaking, high shear mixing, or by using high speed stirrers, blenders, colloid mills, homogenizers, or sonication techniques.

A semi-solid multi-phase oral composition, which can be in the form of a particulate semi-solid dispersion, as disclosed herein, can be prepared as follows: preparing hydrophilic active agent particles and a hydrophobic phase; the hydrophilic active agent particles and hydrophobic phase are combined in an agitated vessel and agitated sufficiently using any method known in the art, for example, Speedmixer (available from flaktek inc., Landrum, SC) can be used to prepare the multi-phase oral composition of the present invention, which can be in the form of a particulate semi-solid dispersion. SpeedMixer^TMThe series of mixing procedures is based on a double rotation of the mixing cup using double asymmetric centrifugal mixing. This combination of centrifugal forces acting on different levels enables very rapid mixing of the entire cup. Optionally, the composition can be heated to facilitate mixing, if desired. The composition was stirred continuously until homogeneous. When the active is included in solid particulate form, the addition of an optional viscosity modifier such as silica may be suitable to keep the particles dispersed and suspended in the composition. Flavors or sweeteners may also be added to one phase of the composition as desired. The composition can then be added to a delivery vehicle as needed.

Methods of using compositions and/or delivery systems

The invention can be applied to the teeth of the consumer by a dental professional in a dental clinic or by the consumer at home. Generally, the recommended treatment time is a period of time sufficient to achieve the desired effect of whitening or active agents.

In practicing the present invention, a user applies the compositions herein comprising an active agent to one or more teeth to achieve a desired effect, such as whitening. The composition may be applied with a brushing device, syringe or unit dose syringe, squeeze tube, brush, pen or brush tip applicator, deer foot applicator, swab, lip gloss applicator, strip removed after application, tray removed after application, or even with a finger. The composition may also be combined with a delivery vehicle, such as a strip of material, a tray, and/or a sponge material, and then applied to the teeth. In preferred embodiments, the compositions or delivery systems herein are barely perceptible when applied to teeth. After the desired period of time has elapsed, any residual composition can be easily removed by wiping, brushing or rinsing the oral surface.

Generally, there is no need to prepare the teeth prior to application of the composition of the present invention. For example, the user may choose to brush or rinse the teeth prior to application of the composition of the present invention, but the oral surfaces need neither be cleaned nor over-moistened with saliva or water prior to application. However, it is believed that if the teeth are dry prior to application, adhesion to the enamel surface will be improved.

The tray appliance may be used as follows. The user or dental professional disperses the present composition in a soft or rigid dental appliance and the participant then places the appliance over the participant's dental arch (or fits the device over his or her teeth to hold the tray in place). Generally, the recommended treatment time is a period of time sufficient to achieve whitening as disclosed above. At the end of the treatment time, the dental appliance is removed, cleaned with water to remove any remaining composition, and then stored until the next use.

The above compositions and delivery systems may be combined in a kit comprising: 1. compositions of the invention and 2. instructions for use; or it comprises: 1. the composition of the invention, 2. instructions for use, and 3. a delivery vehicle. In addition, if the teeth should be irradiated by electromagnetic radiation, the kit may further comprise a source of electromagnetic radiation of an appropriate wavelength and instructions for use, so that the consumer can use the kit in a convenient manner.

Optional electromagnetic radiation treatment

Semi-solid multi-phase oral compositions comprising a bleaching agent as an active agent as disclosed herein are useful for whitening teeth and/or removing stains from the surface of teeth. Furthermore, the whitening efficacy can be further increased by directing electromagnetic radiation of a suitable wavelength to at least one tooth. An apparatus suitable for providing such electromagnetic radiation is shown in fig. 6. Suitable wavelengths may be any wavelength corresponding to the maximum absorption band of the teeth and/or the tooth stain to be bleached. For example, the semi-solid multi-phase oral composition may be irradiated with electromagnetic radiation having one or more wavelengths in the range of about 200nm to about 1200 nm. The electromagnetic radiation may be directed to at least one tooth. Furthermore, more than one tooth may be illuminated. In particular, the electromagnetic radiation may have a peak intensity at a wavelength in a range of about 400, 405, 410, 415, 420, 425, 430, 435, 440, or 445, 446nm to about 450, 455, 460, 465, 470, 475, 480, 481, 485, 490, 495, or 500nm, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein. More specifically, the electromagnetic radiation has a peak intensity at a wavelength in a range from about 425nm to about 475nm, from about 445nm to about 465nm, or wherein the wavelength of the peak intensity of the electromagnetic radiation is similar to the wavelength at which the stain absorbs maximum electromagnetic radiation. The electromagnetic radiation may be directed to at least one tooth during part or all of the wear time of the composition; or after the composition has been removed from the teeth. The electromagnetic radiation may be applied for a period of time at least sufficient for whitening or for achieving the desired effect of the active, such as at least about 1 minute, such as at least about 5 minutes, such as at least about 10 minutes. Electromagnetic radiation may be applied using the procedure disclosed in US 2013/0295525. Preferably, a semi-solid multi-phase oral composition as disclosed herein is applied to at least one tooth and held thereon for a first period of time; directing electromagnetic radiation to the at least one tooth for a second period of time after the first period of time, wherein the first period of time has a duration greater than 50%, preferably 80%, of the total duration of the first and second periods of time; and finally, removing the semi-solid multi-phase oral composition from the at least one tooth.

Suitable sources of electromagnetic radiation include those described herein in the section entitled "clinical protocols".

The semi-solid multi-phase oral composition as disclosed herein can be transparent or translucent to electromagnetic radiation having a wavelength of from about 400nm to about 500 nm. For example, a semi-solid multi-phase oral composition as disclosed herein allows for about 10%, 20%, or 30% to about 0.0001cm, 0.001cm, or 0.01cm to about 0.01cm, 0.1cm, or 0.5cm thick when applied at a thickness of about 0.0001cm, 0.001cm, or 0.01cm to about 0.01cm thickAbout 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the electromagnetic radiation from about 400nm to about 500nm passes through as measured by a spectrophotometer. Specifically, when the semi-solid multi-phase oral composition is applied at a thickness of about 0.1cm, about 80% to about 100% of the electromagnetic radiation of about 400nm to about 500nm passes through, as measured by a spectrophotometer. When applied to a surface area of about 5cm in an amount of about 0.0001 gram, 0.001 gram, or 0.01 gram to about 0.01 gram, 0.1 gram, 1 gram, or 5 gram²To about 20cm²A semi-solid multi-phase oral composition as disclosed herein can allow about 10%, 20%, or 30% to about 40%, 50%, 60%, 70%, 80%, 90%, or 100% of electromagnetic radiation from about 400nm to about 500nm to pass through when on a delivery vehicle or dental tray.

The intensity of the electromagnetic radiation wave impinging on the tooth surface or the outer surface of the carrier (which may be a strip) may be in the range of about 5, 10, 25, 50, 75, or 100mW/cm2 to about 500, 250, 225, 205, 200, 175, 150, 125, 100, 75, 50, 25, 10, or 5mW/cm2, or any other range of values that is narrower and falls within such broader range of values, as if such narrower range of values were all expressly written herein.

Procedure for measuring electromagnetic radiation intensity

The intensity of the electromagnetic radiation can be measured using a photometer (USB 2000+ from Ocean Optics) connected to a UV-VIS 200 micro fiber optic cable with a cosine corrector at its tip (OP 200-2-UV-VIS from Ocean Optics). The photometer is connected to a computer running photometer software (oceanicview 1.3.4 from Ocean Optics). The tip of the fiber optic cable is held directed toward the light source at the location where the light intensity is to be measured. Photons collected at the detector surface are guided through a fiber optic cable to a charge coupled device in a photometer (CCD). The CCD calculates photons arriving at the CCD during a predetermined time period at each wavelength of 200nm to 1100nm and converts these photon counts to spectral irradiance (mW/cm) using a software algorithm²In/nm). Spectral irradiance was integrated from 200nm to 1100nm by software to produce absolute irradiance (mW/cm)²) It is 2An intensity of electromagnetic radiation of 00nm to 1100 nm. Spectral irradiance was integrated from 400nm to 500nm by software to produce absolute irradiance (mW/cm)²) Which is the intensity of electromagnetic radiation from 400nm to 500 nm.

For consumer convenience, the semi-solid multi-phase oral composition as disclosed herein can be provided as a kit comprising an active composition as disclosed herein, a delivery vehicle for easier application, an optional electromagnetic radiation source that emits electromagnetic radiation of a suitable wavelength, and instructions for use.

The compositions of the present invention are useful for human and other animal (e.g., pet, zoo, or livestock) applications.

Examples

The following non-limiting examples further illustrate preferred embodiments within the scope of the present invention. Many variations of these embodiments are possible without departing from the scope of the invention. All examples were carried out at Room Temperature (RT) and atmospheric pressure unless otherwise stated. These semi-solid multi-phase oral compositions are prepared as previously or hereinafter described.

Preparation of semisolid multiphase compositions

A 500 gram batch of examples I and II was prepared by weighing urea peroxide (example 1) or a combination of hydrogen peroxide and polyvinylpyrrolidone polymer (example II) (hydrophilic active agent particles) and petrolatum into a Speedmixer container ("Max 300Long Cup Translucent", product No. 501218 t, available from flaktek inc., Landrum, SC) and stirring at 800RPM for 5 seconds, 1200RPM for 5 seconds, and 1950RPM for 2 minutes in the Speedmixer. The walls of the vessel were then scraped with a plastic spatula and the contents were stirred a second time, at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes. The walls of the vessel were then scraped with a plastic spatula and the contents were stirred a third time, at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes.

A 50 gram batch of example II was prepared by weighing a combination of hydrogen peroxide and polyvinylpyrrolidone polymer (hydrophilic active agent particles) and petrolatum into a Speedmixer container ("Max 100Long Cup Translucent", product number 501221 Lt, available from Flacktek inc., Landrum, SC) and stirring in the Speedmixer at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes. The walls of the vessel were then scraped with a plastic spatula and the contents were stirred a second time, at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes. The walls of the vessel were then scraped with a plastic spatula and the contents were stirred a third time, at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes.

A 50 gram batch of example III was prepared by weighing a composite of hydrogen peroxide and polyvinylpyrrolidone polymer (hydrophilic active agent particles), sodium bicarbonate (hydrophilic active agent particles), mineral oil and petrolatum into a Speedmixer container ("Max 100Long Cup Translucent", product No. 501221 Lt, available from flaktek inc., Landrum, SC) and stirring in the Speedmixer at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes. The walls of the vessel were then scraped with a plastic spatula and the contents were stirred a second time, at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes. The walls of the vessel were then scraped with a plastic spatula and the contents were stirred a third time, at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes.

A gram 200 batch of example IV was prepared by the following steps:

1) petrolatum was weighed into a Speedmixer container ("Max 300Long Cup Translucent", product number 501218 t, available from Flacktek inc.

2) A premix of excess tin (II) fluoride and glycerol was prepared by weighing 4.00 grams of tin (II) fluoride and 7.429 grams of glycerol into a separate Speedmixer container ("Max 40Long Cup Translucent", product No. 501223 Lt, available from Flacktek Inc., Landrum, SC) and stirring in the Speedmixer at 800RPM for 2 minutes.

3) Immediately after step-2, 2.2858 grams of the premix from step-1 were weighed into a Speedmixer container and immediately stirred in the Speedmixer at 800RPM for 2 minutes.

4) The wall of the container was then scraped with a plastic spatula and after about 5 minutes, the contents of the container were stirred a second time at 800RPM for 10 seconds.

5) The walls of the container were then scraped with a plastic spatula and after about 5 minutes, the contents were stirred a third time at 800RPM for 5 seconds.

A gram 200 batch of example V was prepared by the following steps:

1) petrolatum was weighed into a Speedmixer container ("Max 300Long Cup Translucent", product number 501218 t, available from Flacktek inc.

2) A premix of excess tin (II) fluoride and glycerol was prepared by weighing 4.00 grams of tin (II) fluoride and 7.429 grams of glycerol into a separate Speedmixer container ("Max 40Long Cup Translucent", product No. 501223 Lt, available from Flacktek Inc., Landrum, SC) and stirring in the Speedmixer at 800RPM for 2 minutes.

3) Immediately after step-2, 2.2858 grams of the premix from step-1 were weighed into a Speedmixer vessel and immediately stirred in the Speedmixer at 1950RPM for 2 minutes.

4) The walls of the vessel were then scraped with a plastic spatula and, after about 5 minutes, sodium hexametaphosphate was weighed and stirred in a Speedmixer at 1950RPM for 2 minutes.

5) The walls of the container were then scraped with a plastic spatula and after about 5 minutes, the contents were stirred a third time at 1950RPM for 2 minutes.

A summary of examples I-V is provided in Table 1.

TABLE 1 examples I-V

¹Urea hydrogen peroxide adduct, cat # L13940, available from Alfa Aesar, Ward Hill, MA. The solubility in water at 20 ℃ was 800 g/l (80 parts per 100 parts water) according to the safety data sheet provided by the supplier. Through a U.S. standard test sieve with 425 micron openingsNo. 40 was screened.

²Peroxydone K-30 available from Ashland Global Specialty Chemicals Inc., Covington, KY. Solubility in water>40 parts per 100 parts of water (estimated from the information provided in the product data sheet from the supplier for polyvinylpyrrolidone polymer K-30). Sieving was performed through U.S. standard test sieve No. 40 with openings of 425 microns.

³Grade G-2218, available from Sonneborn, LLC., Parsippany, NJ

⁴USP No.2 grade, available from Genesis Specialty Alkali LLC, Philadelphia, PA

⁵Kaydol paraffinic oil grade available from Sonneborn, LLC, Parsippany, NJ

⁶Ultrapure grades, available from Honeywell Specialty Chemicals, seleze, Germany. Sieving was performed through U.S. standard test sieve No. 140 with 106 micron openings.

⁷Glass H Food grade code 338, available from ICL Food Specialties, Creve Coeur, MO. Sieving was performed through U.S. standard test sieve No. 140 with 106 micron openings.

⁸Obtained from Peter Cremer North America, LP, Cincinnati, OH

Comparative example I

A 500 gram batch of comparative example I was prepared by weighing sodium percarbonate (hydrophilic active agent particles) and petrolatum into a Speedmixer container ("Max 300Long Cup Translucent", product number 501218 t, available from flaktek inc., Landrum, SC) and stirring in the Speedmixer at 800RPM for 5 seconds, 1200RPM for 5 seconds, and 1950RPM for 2 minutes. The walls of the vessel were then scraped with a plastic spatula and the contents were stirred a second time, at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes. The walls of the vessel were then scraped with a plastic spatula and the contents were stirred a third time, at 800RPM for 5 seconds, at 1200RPM for 5 seconds, and at 1950RPM for 2 minutes. A summary of comparative example I is provided in table 2.

TABLE 2 comparative example I

H present in hydrophilic bleach particles₂O₂In a weight percent concentration with respect to H present in the total composition₂O₂In percentage by weight concentration of

¹Sodium percarbonate, cat # a16045 from Alfa Aesar, Ward Hill, MA. Water solubility 150 grams/liter (15 parts per 100 parts water) -information from wikipedia released 5 months 21 days 2018. Sieving was performed through U.S. standard test sieve No. 40 with openings of 425 microns.

²Grade G-2218, available from Sonneborn, LLC., Parsippany, NJ

Comparative example II

Comparative example II is a commercially available Crest whitestors Patch white product having 5.25% H2O2 (available from Procter)&Gamble, Cincinnati, OH, USA). This is a composition containing 5.25% hydrogen peroxide (H)₂O₂) The aqueous gel of (a); and thus it is an aqueous gel, the ratio of the concentration by weight of H2O2 present in the aqueous phase to the concentration by weight of H2O2 present in the overall composition is 1.

All examples were carried out at Room Temperature (RT) and atmospheric pressure unless otherwise stated.

In vitro procedure for measuring bleaching efficacy

1. Disks (7.5mm to 7.8mm diameter x 1.2mm to 1.3mm thickness) were cut from the anterior surface of human incisors. The buccal surface is intact and the lingual surface that has been cut from the tooth is flattened. The dental tray is soaked in 15ml to 20ml of water meeting USP specifications in a glass vial for at least 24 hours. This process was repeated for a total of 12 teeth. Baselines L and b were measured on 24 dental trays on three separate days using a hand-held spectrophotometer Konica Minolta 700d and the values averaged over all three days.

2. A set of 12 dental discs was treated with the composition to be evaluated. Specifically, discs of about 19.1mm diameter were cut from the same polyethylene strip as specified in the clinical protocol. About 0.05 grams of the composition was applied to the polyethylene disc as a circular disc of about 9.5mm diameter. The tray was removed from the water and the composition and polyethylene tray were placed on the buccal surface of the tray while it was still wet so that the composition was sandwiched between the tray and the polyethylene tray. Only slight pressure was applied to the polyethylene disc to simulate a strip positioned on the tooth. The sandwich was placed in an oven set at about 34 ℃ (to simulate the condition of the buccal surface of the maxillary anterior teeth) for about 60 minutes.

3. If the semi-solid multi-phase oral composition is used with electromagnetic radiation:

applying electromagnetic radiation to the buccal surface of the dental disc for 10 minutes after 50 minutes of treatment with the semi-solid multi-phase oral composition,

directing electromagnetic radiation through the strip toward the dental tray and through the semi-solid multi-phase oral composition.

Electromagnetic radiation was delivered via a fiber optic cable (model M71L01, from Thorlabs, Newton, NJ, USA) connected to a high power LED (model M455F1, from Thorlabs, Newton, NJ, USA) with a peak intensity wavelength of 455 nm. The LED was operated at 1000mA using an LED driver (model DC2100, or DC4104 paired with DC4100-HUB, available from Thorlabs, Newton, NJ, USA). The exit end of the fiber optic cable is mounted to facilitate reproducible positioning of the electromagnetic radiation against the outer surface of the strip. The exit end of the fiber optic cable was about 7mm from the tooth surface. The intensity of electromagnetic radiation of 400nm to 500nm measured at the central axis of the cone of electromagnetic radiation at this distance needs to be about 175mW/cm²To about 225mW/cm²As measured by the methods disclosed herein.

The radiation was applied to each tray for about 10 minutes.

4. Once the 60 minute treatment with the semi-solid multi-phase oral composition was completed, the polyethylene disc was removed and a paper towel and water were used to remove residual composition on the dental disc.

5. After each treatment, the dental trays were soaked in 15ml to 20ml of water meeting USP specifications in glass vials for at least 24 hours.

6. Finally, b after treatment was measured. This was done on the next three days and averaged for all three days.

7. The mean change in yellowness from baseline (ab) was calculated.

Bleaching efficacy

The bleaching efficacy of examples I-III and comparative example I delivered on strips and used with a source of electromagnetic radiation and measured according to the in vitro procedure specified herein are listed in table 3.

TABLE 3 bleaching efficacy

Table 3 shows that example I achieved a greater reduction in yellowness (- Δ b) than comparative example I. These results clearly demonstrate the surprisingly high efficacy of example I (prepared with urea peroxide) compared to comparative example I (prepared with sodium percarbonate), even though both compositions have the same content of active agent H2O2 (3%).

In particular, these results clearly demonstrate the surprisingly high efficacy of the composition prepared with hydrophilic active agent particles (carbamide peroxide) having a solubility of 80 parts by weight in 100 parts by weight of water (example I) compared to the composition prepared with hydrophilic active agent particles (sodium percarbonate) having a solubility of only 15 parts by weight in 100 parts by weight of water (comparative example I), even though both compositions have the same content of active agent H2O2 (3%). These results clearly show that the solubility of the hydrophilic active agent particles has a surprisingly large effect on efficacy.

Table 3 also shows, example II [ solubility in 100 parts by weight of water>40 parts by weight of hydrophilic active agent particles (complex of hydrogen peroxide and polyvinylpyrrolidone polymer)]A surprising large reduction in yellowness (- Δ b) of 2.57 was achieved, while comparative example I [ prepared with hydrophilic active agent particles (sodium percarbonate) having only 15 parts by weight solubility in 100 parts by weight of water]A yellowness reduction (- Δ b) of only 0.84 was achieved, even though both compositions wereWith the same content of active agent H₂O₂(3%). These results clearly show that the solubility of the hydrophilic active agent particles has a surprisingly large effect on efficacy.

Table 3 also shows that example III achieved a greater reduction in yellowness (- Δ b) than example II. These results clearly demonstrate the surprisingly high efficacy of example III (prepared with a complex of hydrogen peroxide and a polyvinylpyrrolidone polymer mixed with sodium bicarbonate) compared to example II (prepared with a complex of hydrogen peroxide and a polyvinylpyrrolidone polymer, but without sodium bicarbonate), even though both compositions have the same content of H₂O₂(3％)。

In particular, these results clearly demonstrate the surprisingly high efficacy of a composition prepared with two or more oral care hydrophilic active agent particles that are typically incompatible with each other combined in the same composition (example III) compared to a composition prepared with only one oral care active agent (example II). These results also clearly demonstrate that sodium bicarbonate has a surprisingly large impact on bleaching efficacy when mixed with hydrophilic bleach particles.

Clinical bleaching efficacy of example II and comparative example II

Bleaching efficacy of example II was measured according to the clinical protocol specified herein. In particular, this is a single-center clinical study conducted on adults who have never undergone professional, non-prescription, or research tooth bleaching treatments. All participants were at least 18 years old, had all four measurable maxillary incisors, and had no self-reported dental hypersensitivity.

Example II (20 participants, mean L72.7 and mean b 15.4)

The participants were treated with the oral composition once daily for 60 minutes of maxillary anterior teeth using a polyethylene strip as a delivery vehicle. The polyethylene strips were 66mm by 15mm in size and 0.0178mm in thickness. 0.6 to 0.8 grams of the oral composition was applied over each polyethylene strip prior to application to the maxillary anterior teeth.

The distribution of the maxillary strips and all applications was supervised by the clinical field staff. For each treatment, participants worn strips with oral composition for a total of 60 minutes. After 50 minutes of wearing each strip, a trained hygienist applies electromagnetic radiation to the facial surface of the maxillary anterior teeth for 10 minutes. Electromagnetic radiation is directed through the strip and through the oral composition to the teeth. Electromagnetic radiation is delivered using a source of electromagnetic radiation as described herein in the section entitled "clinical protocol". The intensity of electromagnetic radiation of 400nm to 500nm measured at the central axis of each cone of electromagnetic radiation exiting at the exit face of the transparent window through which the electromagnetic radiation passes towards the maxillary anterior teeth through the transparent window was measured to be about 175mW/cm²To about 225mW/cm²As measured by the procedure disclosed herein.

Digital images were collected at baseline and the day after 1 st, 2 nd and 3 rd treatment. Participants treated with example II exhibited a statistically significant (p <0.001) reduction in yellowness increment (-ab) relative to baseline at all time points tested; furthermore, on the day after the 2 nd and 3 rd treatments, an increase in brightness (Δ L) and (p <0.001) was observed in this group.

The inclusion of 5.25% H in the aqueous gel was measured in a clinical study₂O₂Of a final concentration of the second comparative composition (comparative example II-with 5.25% H)₂O₂The Crest Whitestrips product). In particular, the study of comparative example II was a controlled single-center clinical trial. The target population was an adult participant who had not previously been exemplified for tooth whitening. With 5.25% H delivered onto polyethylene tape₂O₂The above comparative aqueous gel (comparative example II) of (a) treated the participants. The group (20 participants, mean L72.8 and mean b 16.4) was worn with strips once a day for 60 minutes for 14 days.

Digital images were obtained at baseline and the day after the 7 th and 14 th treatments. Comparative example II (with 5.25% H) delivered by wearing on a strip₂O₂Aqueous gel of (d) and last for 60 minutes (as in the clinical examples previously described)II same time length) are shown in table 4.

TABLE 4 clinical bleaching efficacy

After 7 treatments, comparative example II (delivered on tape with 5.25% H)₂O₂For 60 minutes) produced an average change in yellowness of-0.985, whereas example II (also delivered on a tape and used with an electromagnetic radiation source) achieved an average change in yellowness of-1.14 after only 1 treatment, despite its lower H compared to the hydrogel used in comparative example II₂O₂Concentration (3% H)₂O₂Relative to 5.25% H₂O₂). Similarly, comparative example II produced an average change in yellowness of-1.43 after 14 treatments, while example II achieved an average change in yellowness of-1.73 after only 2 treatments, despite having a lower H compared to the aqueous gel₂O₂Concentration (3% H)₂O₂Relative to 5.25% H₂O₂). These results also clearly demonstrate the surprisingly high efficacy of example II (delivered on a tape and used with a source of electromagnetic radiation as disclosed herein), despite its lower H compared to the comparative hydrogel-containing used in comparative example II₂O₂Concentration (3% H)₂O₂Relative to 5.25% H₂O₂)。

The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Rather, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm".